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Part I
Antiretroviral drug resistance develops during treatment of human immunodeficiency 
virus type 1 (HIV-1) infection, but the consequences of drug resistance on HIV-1 
pathogenesis and the clinical relevance of these consequences have not been thoroughly 
studied. These questions can be addressed in an animal model of natural lentivirus 
infection. The present study examined site-directed mutants of a pathogenic molecular 
clone of feline immunodeficiency virus (FIV), FIV-pPPR, as potential models for 
studying the effects of (-)-P-L-2’,3-dideoxy-3-thiacytidine (3TC, lamivudine) resistance 
on lentiviral pathogenesis. A methionine-to-valine (Ml83V) mutation at codon 183 of 
FTV, located in the highly conserved YMDD motif of the RT-encoding region of the pol 
gene, conferred high-level phenotypic resistance to 3TC and cross-resistance to the 
related COm^OUnd, (-)-R-T 1 ^ -Hif<«»r>Yy-S-flimrn-^’. thiapx i f j f(-)-FTC]. 3TC 
resistance was similar in magnitude to HIV-1 with a homologous mutation at codon 184 
(Ml84V) that characteristically develops in 3TC-treated HIV-1-infected patients. This 
FTV-pPPR Ml83V mutant will be useful in studying the effects of 3TC resistance on 
lentiviral pathogenesis.
Part II
The ADV-Utah 1 biological isolate of Aleutian mink disease parvovirus (ADV) 
replicates efficiently and is highly pathogenic in mink but cannot be propagated in vitro. 
The ADV-G molecular clone derived from cell culture-adapted ADV-Utah 1 does not 
replicate or cause disease in adult mink but can be propagated to high titers in vitro. 
Recently, the first chimeric viruses of ADV-Utah 1 and ADV-G that could replicate both 
in vitro and in vivo and cause pathogenesis in mink were described. ADV-G/U-8 
infection was associated with higher antibody titers and more severe histopathological 
lesions than ADV-G/U-10. These chimeras, however, differed by only one capsid and 
three nonstructural protein amino acid changes. The purpose of the current studies was to 
determine whether differences in in vivo replication and pathogenesis between G/U-8 and 
G/U-10 were attributable to capsid or nonstructural protein changes. In order to answer 
this question, additional chimeric viruses were constructed, propagated in vitro, and used 
to infect mink. Antiviral antibody responses, viremia, hypergammaglobulinemia, and 
histopathological lesions indicated that codon 352 of the capsid protein influenced in vivo 
replication and pathogenesis, but the effects of the nonstructural protein likely played an 
interactive role as well.
ii
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PREFACE
My experiences as a graduate student held many surprises and lessons for me.
The biggest surprise was that the most important things I learned during the past four 
years were about life, not about science. There were times when the obstacles seemed so 
arbitrary and unfair and insurmountable that I felt certain they could not be overcome. 
Other moments were filled with the most extreme loneliness, fear, and self-doubt I have 
ever experienced. So many things seemed to be completely beyond my control. And, yet, 
through the toughest of times, there were those champions of moral decency and integrity 
who, by their own living examples, supported and encouraged me to be honest and fair, 
yet unwavering in my convictions, despite the consequences. They continued to believe 
with convincing sincerity that strength of personal character was more important than 
scientific or career accomplishments. And that, in fact, sooner or later, a life lived 
pursuing truth could overshadow the temporary power of politics. I am indebted to these 
advisors and role models who not only helped me weather difficult times, but who also 
gave me hope for the future: Drs. Don Christian, Jim Gannon, Walt Hill, and Bill 
McBroom, and my parents, Windell and Johann McCrackin. The influence of these 
people helped me turn a situation ripe for prolonged, destructive anger and bitterness into 
an opportunity for unexpected positive personal and professional growth and a great 
lesson in forgiveness.
I am also grateful for the wonderfully rewarding friendships that were a result of 
being in the right place at the right time. Drs. Jim Battisti, Angelika Longacre, Rachel
iii
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LaCasse, Scott Knight, Jim Fox, Klaus Jensen, Heidi Super, and Karin Peterson were all 
a help to me personally and professionally. Doug McBroom, Joan Strange, Deb Nycz, 
Betsy Kimmel, Kathy Follis, Jim Wolfinbarger, Cynthia Favara, Kathy Wehrly, Don 
Dale, Dirk Whitsitt, Bob Evans, and Gary Hettrick taught me technical aspects of my 
work as well as to love what I do every day. A special thanks is due Doug McBroom for 
being the embodiment of true, lasting friendship. I am also thankful to my graduate 
committee for their time, understanding, and standards: Drs. Michael F. Minnick, 
Marshall E. Bloom, Rich Bridges, George L. Card, Walt E. Hill, and D. Scott Samuels. 
And to one of my biggest supporters and one of the finest gentlemen and veterinary 
pathologists I will ever know, Dr. William J. Hadlow, thank you very much for 
histopathological i n tern ret ations > clinical mink advice, stimulating discussions, and for 
being enthusiastic about my work.
The time I was able to spend at the Rocky Mountain Laboratories was an 
especially productive, rewarding, and healing time for me. I will always be indebted to 
Drs. Marshall Bloom and Bruce Chesebro for making this opportunity happen for me. 
Their personal support and encouragement of me and my career efforts has given me 
renewed confidence in myself and the scientific community. They, as well as other 
members of the Laboratory of Persistent Viral Diseases (special mention to Drs. Don 
Lodmell and John Portis), pushed my scientific thinking beyond the limits of the 
restrictive mental “box” I had created for myself in clinical veterinary practice. They 
opened up new possibilities and new ways of thinking on a broader scale than I had 
allowed myself previously. They also convinced me that I was ready for the next step
iv
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into independence as a biomedical researcher. Marshall, in particular, not only put up 
with but also cooperated with my demands to do certain things certain ways when it came 
to animal research. I know I was a pain and at times irritatingly exacting about details 
concerning things that may have seemed unimportant at the time. Thanks for indulging 
me, Marshall. I have already made plans to start saving for your future therapy as a result 
of my year and a half in your lab. You deserve it.
And, finally, because there are just not enough appropriate words for describing 
the amazing and selfless contributions of my husband, Mike, thank you. I will always 
love you and could not have done this without you.
This work was supported in part by the Division of Biological Sciences, The 
University of Montana, Missoula, MT; the Fur Breeders Agricultural Cooperative; and 
the Mink Fanners Research Foundation.
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P A R T I
OXATHIOLANE NUCLEOSIDE ANALOG RESISTANCE IN A PATHOGENIC 
MOLECULAR CLONE OF FELINE IMMUNODEFICIENCY VIRUS
CHAPTER 1 
INTRODUCTION
DRUG RESISTANCE
Introduction. The emergence of drug-resistant pathogens, including bacteria, fungi, 
parasites, and viruses, represents the newest frontier in healthcare challenges facing the 
developed world. Methcillin-resistant Staphylococcus aureus, multidrug-resistant Gram 
negative enteric bacteria, and isoniazid-resistant Mycobacterium tuberculosis are 
currently responsible for significant morbidity and mortality in the United States. 
Fluconazole-resistant Candida albicans (1) and flucytosine-resistant Cryptococcus 
neoformans (103) are fungal opportunists particularly causing problems for 
immunocompromised patients. Parasites such as Leishmania amazonensis and 
Trypanosoma cruzi carrying genes encoding multidrug resistance (41) and azole 
resistance (8). Many viruses have also developed important drug resistance, including 
influenza A, herpes simplex virus (HSV), poxviruses, poliovirus, and human 
immunodeficiency virus type 1 (HIV-1) (86).
Antiviral drug resistance is not a new phenomenon. Reports of viruses resistant to 
antiviral agents first appeared in the 1960s and included influenza A (amantadine) (11),
1
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HSV (iododeoxyuridine) (40), poxviruses (thiosemicarbazone) (3), and poliovirus 
(guanidine) (61). Widespread awareness of and interest in antiviral drug resistance did 
not occur until the 1980s when the difficulties of treating HIV-1-infected patients were 
well-publicized in the popular press. Advances in molecular biology during the 1980s 
also provided sophisticated new research tools for studying the small genomes of many of 
the pathogenic viruses.
At least four factors are believed to work together to make the development of 
drug resistance likely for any given virus. These factors are viral mutation frequency, 
magnitude and rate of vims replication, mutability of the viral target, and selective 
pressure of the antiviral chug (86). Retroviruses fit these criteria particularly well for 
being likely candidates to develop drug resistance. The in vivo mutation frequency of 
lentivimses, such as HIV-1, is approximately 10"* to 10'5 per nucleotide per round of 
replication (54). This means that approximately one mistake occurs in a 10 kilobase 
retroviral genome every time it is replicated. This relatively high mutation frequency, 
combined with a high rate and magnitude of viral replication ( 1010 new HTV-1 virions per 
day per infected individual) (34), creates a diverse viral population capable of having 
almost any mutation pre-existing at any time (86) before drag selection pressure is 
present. The viral target of many antiretroviral chugs, the reverse transcriptase (RT) 
enzyme, has been shown to mutate rapidly in the presence of natural substrate analogs 
containing distinctive sugar moieties, such as 3 -azido-3-deoxythymidine (AZT) and (-)- 
p-L-2’,3-dideoxy-3-thiacytidine (3TC) (86). Drug selection pressure is dose-dependent. 
At suboptimum drug doses, chug-resistant quasispecies replicate well, while wild-type
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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virus is inhibited. Once the drug dose surpasses a critical concentration, even drug- 
resistant virus replication is inhibited, slowing the overall rate and magnitude of viral 
replication (87).
The importance of trying to reduce retroviral replication rate to the lowest 
possible level in order to successfully control lentiviral disease cannot be overstated. The 
replication capabilities and persistence of HIV-1 mean that even low levels of virus 
replication will eventually be detrimental to the host. Treatment attempts that have been 
the most successful at significantly reducing virus replication are combination drug 
therapies directed against more than one viral target. The current approach, called highly 
active antiretroviral therapy (HAART), combines two RT inhibitors and a protease 
inhibitor. While several other novel targets are currently being investigated, including 
virus binding and entry (43), integrase (44), rev (20), and RNA secondary structure (20), 
nucleoside analog RT inhibitors continue to be the basic foundation of current 
antiretroviral therapy.
Reverse transcriptase. RT is a viral-encoded RNA-dependent DNA polymerase that 
plays a crucial role in the life cycle of retroviruses. Double-stranded proviral DNA that 
can be integrated into the host cell genome must be made from single-stranded genomic 
viral RNA. The process of reverse transcription by RT involves first making a minus- 
sense strand of DNA complementary to the plus-sense genomic RNA. The viral RNA 
template is then degraded by the RNase H activity of RT as a complementary plus-sense 
DNA strand is synthesized based on the new minus-sense DNA template. Blocking this 
step of the retrovirus life cycle inhibits viral replication because to persist inside the host
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cell and to be transcribed by the host cell machinery, RNA polymerase n , proviral DNA 
must be produced and integrated into the host cell genome (99).
RT is a heterodimer composed of two subunits, p66 and p51. The larger subunit 
contains the active sites of polymerase activity and RNase H activity. The smaller 
subunit is identical in primary amino acid sequence to the larger subunit but lacks the C- 
terminal portion that makes up the RNase H active site. The tertiary structure of RT has 
been compared to a human hand in shape, exhibiting palm, fingers, thumb, and 
connection domains (99). The palm domain of the large subunit contains the polymerase 
active site, consisting of three aspartic acid residues (residues 110, 185, 186) (6,49). Two 
of these aspartic acid residues are part of the YXDD motif, the most highly conserved 
portion of RT across species (107).
The ability to easily measure RT function and its inhibition on the enzyme level in 
vitro has greatly added to the understanding of RT function and the interactions of some 
inhibitors. RT is not posttranslationally modified, so recombinant RT has the same 
enzymatic properties as virion RT (99). p51 subunits can be produced by either treating 
recombinant RT (rRT) with species-specific protease or allowing autodigestion of 
bacterial lysates containing rRT at 4°C overnight (D. G. McBroom, unpublished data). 
While data describing RT kinetics, inhibition, processivity, and fidelity can be generated 
in vitro in convenient test tube reactions, their meanings can easily be misleading if not 
interpreted in light of more physiologically relevant data. For instance, Mansky and 
Temin showed that the in vivo mutation rate of HIV-1 is lower than that predicted from 
the in vitro measured fidelity of purified HIV-1 RT (54). Also, it is well known that the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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phenotypic resistance of AZT-resistant patient isolates often does not correlate with in 
vitro data generated using purified RT (23,47,56).
RT inhibitors. The two classes of antiviral drugs that have been used clinically to inhibit 
RT function are the nucleoside analog inhibitors and the non-nucleoside RT inhibitors 
(NNRTI) (20). NNRTIs are noncompetitive RT inhibitors that exhibit very specific 
binding, so NNRTIs effective against HIV-1 RT are not useful for RT of other species. 
Resistance to NNRTIs develops very rapidly in both cell culture and in treated patients, 
so their usefulness has been limited. However, of the antiretroviral agents currently 
available, the relationship between the development of drug resistance and treatment 
failure is most straightforward for the NNRTIs (88,89).
Nucleoside analog inhibitors are the most commonly used antiretroviral drugs to 
treat lentivirus infections. Several of them, such as AZT, ddl, and ddC, were used for 
cancer treatment prior to their use as antiretrovirals because of their ability to inhibit 
cellular polymerases (20). In fact, this may be partly responsible for the toxicity 
associated with high doses of some of the nucleoside analogs. Nucleoside analogs 
function as molecular mimics of the natural substrates of RT, the nucleoside 
triphosphates. The marketed chugs must be metabolized intracellularly to their active 5- 
triphosphate forms. Their mechanisms of action include competitive inhibition and chain 
termination (28,62).
Transmission of drug-resistant virus. Drug resistant isolates of HIV-1 cause problems 
not only in infected patients, but also as infectious pathogens (13). Initially, it was 
suspected that drag-resistant isolates may not be present in high enough numbers or
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6
replicate well enough to survive in vivo transfer from one individual to another (13). 
However, transmission of AZT-resistant virus from one person to another has been 
documented for a fetus from an infected mother (93), by parenteral inoculation (2,24), 
and by sexual intercourse (12,22,104). It has not yet been determined if infection with 
AZT-resistant HIV-1 follows a different clinical course or a different rate of virological or 
immunological disease progression (13). The number of reports of natural transmission 
of AZT-resistant HIV-1 suggests that the incidence of newly-diagnosed HIV-1-infected 
patients carrying drug-resistant vims populations will continue to increase. It will be 
important to understand how the biology of initial drug-resistant viral infection may vary 
from infection with wild-type vims so that appropriate treatments can be devised.
FELINE IMMUNODEFICIENCY VIRUS: ANIMAL M ODEL FO R HIV-1 
Clinical Syndrome. Feline immunodeficiency vims (FIV) is a natural disease of the 
domestic cat population, as well as wild, giant cats of North America and Africa (68). 
Clinical disease caused by FIV in domestic cats is almost identical to that of HIV-1 in 
humans (21,71,72,76,109). Cats experience an acute phase of disease characterized by 
lymphadenopathy, fever, malaise, viremia, and a decrease in CD4+ T cells (71). This is 
followed by a long latent period of several years identified by high antibody and low viral 
antigen levels in the peripheral blood. Clinical decline is marked by a resurgence of 
viremia, anorexia, poor haircoat, weight loss, gingivitis, neurological signs, and 
opportunistic infections (21,71,72,76,109).
Use of specific pathogen free (SPF) cats in experimental infection consistently
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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produces acute phase disease, including immunological and neurological abnormalities 
and behavioral disorders (33). In addition to classical alterations in the CD4+ T cell 
count, functional immune suppression as evidenced by susceptibility to a normally 
avirulent strain of Toxoplasma gondii was clearly demonstrated in cats infected with FIV- 
NCSU[ (15). Recent experimental work on the neurovirulence of FIV and its 
mechanisms showed that neonatal kittens infected with a cerebrospinal fluid isolate of 
FIV were neurodevelopmentally delayed compared to control kittens and kittens infected 
with a peripheral blood mononuclear cell (PBMC) isolate of FIV (78).
Neurodevelopment was assessed by determining the age at which infected and control 
kittens could playfully interact, walk, run, air right, walk along a plank, and acquire a 
blink reflex (78). In addition to virus strain, immune suppression likely played a role in 
neurovirulence. Kittens infected with a PBMC isolate of FTV, FIV-Petaluma, and treated 
with cyclosporin A, a potent T cell inhibitor, showed delay of neurodevelopment and 
reduced TV-acetyl aspartate/creatine ratios in the brain (78). Another group studying the 
neurovirulent FTV-MD biological strain of FTV recently showed that infected SPF cats 
exhibited higher basal activity levels and higher distractibility during a spatial learning 
task compared to control cats (96). Field observations, locomotion tests, traversing 
planks of varying widths for a food reward, and a spatial learning task were used to 
measure behavior and cognition in adult cats that were infected with FTV-MD as kittens 
(96). Two investigative groups have also shown that neuronal loss, a hallmark of 
neuropathogenesis in HTV-1 infection, occurs with experimental FIV infection (7,79).
The target cells of FIV infection in the central nervous system are likely astrocytes and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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microglia (17,18), with neuronal injury occurring secondarily (26).
Microscopic neuropathologic changes have been documented in both naturally 
infected (18) and experimentally infected cats (19,72,76). Lesions included mild 
histiocytic and lymphocytic infiltration of vessel walls in cats infected with the minimally 
neuropathogenic FIV-Petaluma (19). The characteristically neuropathogenic FTV-MD 
biological isolate was associated with cortical (72) and subcortical (72,76) perivascular 
lymphocytic or monocytic infiltrates. In addition, neuronal satellitosis was evident in the 
deep cerebrocortical lamina of the parietal/occipital region of the brain (76), and glial 
nodules were seen in the parahippocampal gyrus (72). These histopathological 
abnormalities are similar to those seen in HTV-1 infection (18) of the central nervous 
system with the exception of the low incidence of multinucleated giant cells (26). 
Pathogenic molecular clones of FTV. Pathogenesis studies in the FIV model in the 
United States were initially done using various clinical isolates, or swarm populations 
(21,71,72,76,109). Lack of a completely sequenced pathogenic molecular clone limited 
drug resistance studies based on single point mutations. Phillips, et. al., developed the 
FTV-pPPR molecular clone in 1990 (74). The complete sequence is registered in the 
GenBank database (accession no. M36968) and is carried in a pUCl 19 background along 
with 150 - 300 bases of feline genomic DNA at the 5 ’ and 3’ ends of the virus (74). The 
immuno- and neuropathogenesis of FIV-pPPR have been extensively characterized in 
SPF cats (73). Immunological abnormalities in acute phase disease include plasma 
antigenemia, plasma viremia, inversion of the CD4+/CD8+ T cell ratio, and decreased 
total CD4+ T cell counts. Later, a rise in antibody titers and decrease in viral load are
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seen (73). Neurological abnormalities observed include delayed pupillary reflex, delayed 
righting reflex, and anisocoria. Approximately 50% of SPF cats infected with wild-type 
FIV-pPPR develop posterior paresis within 6 months of infection (73). Measurable 
neurological dysfunctions include delayed brainstem auditory evoked responses (BAER), 
visual evoked potentials (VEP), and peripheral nerve conduction velocities (33,72,73). 
These electrophysiological changes all occur during the first six months following 
infection and can be detected even in the face of clinical normalcy. Sleep disturbances 
and electroencephalographic (EEG) alterations have been measured one year 
postinfection with the FIV-MD biological strain of FIV (80). These findings parallel 
early neuropsychiatric symptoms seen in HTV-1-infected patients, often heralding the 
onset of AIDS.
A primarily immunopathogenic molecular clone of FIV, FIV-NCSU,-JSY3, was 
developed in the laboratories of Wayne A. F. and Mary B. Tompkins in 1996 (110). A 
lambda clone containing the full-length FTV genome was determined infectious for cats 
(110). The cloned viral genome has since been transferred into a plasmid vector, and this 
entire plasmid is currently being sequenced (Tedd Childers, personal communication, 
March, 1999). At the time the present work was started, this clone was not characterized 
sufficiently to be used for molecular virology studies; however, it will provide another 
alternative to FIV-pPPR for a pathogenic molecular clone of FTV in the future.
In comparison to FIV-pPPR, the JSY3 molecular clone of FIV-NCSU, was not 
reported to have primarily neurologic manifestations in experimentally infected cats but 
rather signs of immunologic impairment very similar to the biological parent vims. The
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JS Y3 molecular clone maintained tropism for primary cells of cats, induced a significant 
inversion of the CD4+/CD8+ ratio by six weeks postinfection, provoked a strong antibody 
response to gag and env antigens, and stimulated a heavy burden of FIV pro virus in 
PBMC during acute-stage infection (110). Most convincingly, SPF cats experimentally 
infected with the JSY3 clone of FIV-NCSU! were susceptible to a normally avirulent 
strain of Toxoplasma gondii by 29 weeks postinfection (110). These results demonstrated 
severe functional immunosuppression associated with FTV-NCSUr JSY3 infection.
Drug resistance of nucleoside analogs to FIV in vitro. Nucleoside analog drug 
resistance in the FIV model has been studied both at the enzyme level as well as the 
phenotypic level using a nonpathogenic molecular clone of FIV in an immortalized cell 
line. The work presented in this thesis represents the first attempts to study nucleoside 
analog drug resistance using a pathogenic molecular clone in primary cell culture of 
PBMC.
FIV RT of the nonpathogenic molecular clone, FIV-p34TF10 (97), is similar to 
HTV-1 RT in physical properties, catalytic activities, and sensitivity to the active forms of 
nucleoside analogs (63,64,66). FTV RT has also been expressed in a recombinant protein 
expression system and used extensively to study RT kinetics (65).
The first reported AZT-resistant lentivirus selected in cell culture was 
characterized in Crandell feline kidney cells (CrFK) using the biological isolate, FIV- 
Petaluma (82). Subsequently, resistant mutants of FIV-p34TF10 to ddl (27), ddC (59), 
d4T (113), FTC (94), 3TC (95), AZT and ddl (27), and AZT and 3TC (95) were selected 
in vitro. Single point mutations have proven to be responsible for the observed drug
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resistance of these mutants. Limiting the study of these mutants in vivo is the inability of 
FIV-p34TF10 to cause clinical disease in experimentally infected cats. Limiting the 
direct application of in virro-generated drug resistance information from the FIV system 
has also been the nonhomologous nature of the selected FIV mutations to HIV-1, with the 
exception of the M183T mutation selected with FTC (94). This mutation has only been 
seen during in vitro selection procedures in HIV-1 (42); it has never been reported from 
an oxathiolane nucleoside-treated HIV-l-infected patient. Subsequently, its clinical 
relevance remains unclear.
Drug resistance of nucleoside analogs to FIV in vivo. Previous in vivo work in cats 
using nucleoside analogs targeted feline leukemia virus (FeLV) and primarily involved 
the drugs, AZT (57,58,98,111) and ddC (77,98,112). Limited work has been reported 
treating FIV infection with AZT (32) and ddC (53). Interest in the phosphonoformates, 
pyrophosphate analogs that do not require intracellular activation (13), also began in the 
FeLV model (35). Experiments evaluating the effectiveness of phosphonoformates in 
treating FIV-infected cats used the drug PMEA (30,31,75), which was limited by toxicity, 
and other phosphonoformate derivatives, [(R)-PMPDAP] (lOl)and FPMPA (31), which 
showed promise for clinical use. Current therapy in the United States for naturally FIV- 
infected cats includes AZT and 3TC (Julie Levy, personal communication, 1999). Drug 
resistance mutations have not yet been reported in naturally infected, nucleoside analog- 
treated cats. However, AZT resistance mutations have been studied to a limited degree in 
macaques using simian immunodeficiency virus (SIV) (102).
As mentioned above, the work reported in this thesis represents the first attempts
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to study drug resistance mutations in a pathogenic molecular clone of FIV in primary cell 
culture of PBMC. The ultimate goal of transferring the technology of studying drug 
resistance into primary cells was to be able to study in virro-engineered and characterized 
mutants in the in vivo cat model. This would allow the comparison of pathogenicity 
between wild-type and specific drug-resistant mutants in experimentally infected SPF 
cats. These comparisons may be helpful in unraveling the question of whether drug- 
resistant mutants are more or less pathogenic than wild-type virus. The answer to this 
question may significantly impact the therapy of FIV-infected cats and HTV-1-infected 
people.
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CHAPTER 2 
MATERIALS AND METHODS
ANIMALS
Uninfected specific pathogen free (SPF) cats were used as blood donors in order 
to harvest peripheral blood mononuclear cells (PBMC) for primary cell culture. Cats 
were neutered adults, three females and one male, on loan from the laboratory of Niels C. 
Pedersen (University of California, Davis, CA). Housing and husbandry practices were in 
strict conformance with federal guidelines. All animal procedures were approved by the 
Institutional Animal Care and Use Committee at The University of Montana.
Cats were tranquilized with 0.25 mg acepromazine maleate and 20 mg ketamine 
hydrochloride intravenously in the saphenous vein. Whole blood was collected by aseptic 
jugular venipuncture and transferred to sodium heparin vacuum tubes (Becton-Dickinson, 
Franklin Lakes, NJ). Heart rate and respiratory rate were monitored until the cats were 
stemally recumbent.
CELLS
Crandell feline kidney cells. Crandell feline kidney cells (CrFK) (American Type 
Culture Collection, Rockville, MD) were maintained in cell culture as previously 
described (66).
Peripheral blood mononuclear cells. SPF PBMC were separated over a Ficoll-Hypaque 
gradient (Pharmacia, Uppsala, Sweden) from heparinized whole blood diluted with an
13
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equal volume of Hank’s balanced salt solution. PBMC were maintained in RPMI-1640 
medium containing human recombinant IL-2 (100 u/ml) (gift of Niels C. Pedersen), 
penicillin (50 IU/ml), streptomycin (50 pg/ml), L-glutamine (2 mM), HEPES (N-2- 
hydroxyethylpiperazine-AT-2-ethanesulfonic acid) buffer (10 mM), P-2-mercaptoethanol 
(5 x 10'5M), sodium pyruvate (1 mM), and 10% heat-inactivated fetal bovine serum 
(HyClone, Logan, UT) after an initial 48-h mitogenic stimulation with conconavalin A 
(con A) (1 pg/ml).
VIRUS
Pathogenic molecular clone. First passage virus stocks of the pathogenic molecular 
clone, FIV-pPPR, were prepared by transfecting CrFK cells with proviral plasmid DNA 
(74) purified from the J5 strain of Escherichia coli JM109 using a Wizard Plus miniprep 
kit (Promega, Madison, WI). E. coli JM109-J5 containing the FIV-pPPR plasmid was a 
generous gift of Tom R. Phillips (The Scripps Research Institute, San Diego, CA). 
Transfection was done using DOTAP liposomal transfection agent (Boehringer 
Mannheim, Indianapolis, IN) as recommended by the company, then transfected CrFK 
were cocultured for 48 h with SPF feline PBMC. Supernatants containing nonadherent 
PBMC were then transferred to new flasks and cultured separately. Supernatants from 
infected PBMC cultures were monitored for rising RT activity measured on a poly(rA)- 
oligo(dT)10 template as previously reported (66). Cell-free virus was harvested on the 3 to 
5 days of maximal RT activity, clarified by centrifugation for 10 min at 500 x g, pooled, 
and filtered through a 0.45 pm filter into aliquots for -80°C storage.
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Natural virus population. The propagation of a natural virus population, named FIV- 
Maxam, was done by culturing PBMC from an untreated, naturally infected cat with 
equal numbers of uninfected SPF feline PBMC as previously published (71).
Heparinized whole blood was a kind gift of Alan B. Applebury (Valley Pet Clinic, 
Hamilton, MT). Plasma screening was positive for FIV antibody and negative for feline 
leukemia virus (FeLV) antigen (IDEXX, Portland, ME). Supernatant RT activity was 
measured and cell-free virus harvested on 5 days of peak RT activity. Cell-free virus was 
processed as for FIV-pPPR stocks.
Three parameters used to verify the identity of the cultured virus included 
successful PCR amplification of the RT-encoding region of the pol gene, maximal RT 
activity in the presence of Mg2+ rather than Mn2+ cations to distinguish from FeLV, and 
the ability to infect uninfected PBMC. First, genomic DNA was harvested from infected 
PBMC using a QIAamp tissue kit (Qiagen, Inc., Valencia, CA) and was used as template 
for PCR amplification using FIV-p34TF10 RT primers four (5- 
GTAATGTTTGTGTCTTAGAAGGATAACTC-3 0 and six (5- 
ATCATATCCTGCATCTTCTGACCT-3’). A 25-min hot start at 94°C followed by 30 
cycles of 94°C for 30 sec, 58°C for 30 sec, and 72°C for 2 min produced a 2-kb product 
identical in electrophoretic mobility to the FIV-pPPR positive control (data not shown). 
Next, RT analysis of crude lysates of FIV-pPPR and FIV-Maxam on a poly(rA)- 
oligo(dT)l0 template in the presence of varying concentrations of either Mg2+ or Mn2+ 
ions was done as previously described (71), demonstrating maximal Mg2+-dependent RT 
activity at 5 mM for both viruses (Fig. 2.1). Finally, stored viral stocks were thawed and
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Figure 2.1. Reverse transcriptase (RT) activity of FTV-pPPR and FTV-Maxam in the 
presence of varying concentrations of Mg2* and Mn2+. FTV-pPPR is a pathogenic 
molecular clone, and FTV-Maxam is a clinical isolate. Viruses were propagated in 
peripheral blood mononuclear cells (PBMC) of specific pathogen free (SPF) cats. Crude 
lysates of cell culture supernatants were tested for RT activity on apoly(rA)-oIigo(dT)10 
template in the presence of various concentrations of the cations, magnesium and 
manganese. Magnesium-dependent RT activity is characteristic of feline 
immunodeficiency virus.
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incubated with uninfected SPF feline PBMC. Rising RT activity confirmed viral stock 
infectivity (data not shown).
ASSAYS
Introduction. While titering and drug susceptibility testing for HIV-1 biological isolates 
and infectious molecular clones are standardized in human PBMC (39), these types of 
assays were not routine nor standardized for feline PBMC when this work was begun. 
These assay conditions were maximized for feline PBMC in 24-well plates for an assay 
endpoint of 7 days postinfection (data not shown). This timing was similar to that used 
for HIV-1 testing as recommended by the AIDS Clinical Trials Group (39,55).
Virus titering. Vims stocks were titered in two 24-well plates by culturing quadruplicate 
replicas of 2 x 105 infected SPF feline PBMC per well (0.7 ml medium per well). 
Infections were 5-fold serial dilutions of vims starting with either a 1:5 dilution or 1:10 
dilution (one plate for each) (modification of original protocol provided by Lawrence E. 
Mathes, The Ohio State University, Columbus, OH). Fresh medium was added 72 h 
postinfection (0.5 ml/well), and 0.3 ml supernatant was harvested from each well 6.5 days 
postinfection and stored at -80°C.
Samples were tested for p24 antigen expression using an antigen capture ELISA 
assay (antibodies kindly provided by Niels C. Pedersen) (14). Wells designated positive 
were those with detectable levels of antigen more than 2 standard deviations greater than 
the mean of the negative control wells. Titers expressed as tissue culture infective doses 
for 50% of the cultures (T d D S0) were calculated using the Spearman-Karber equation
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(37).
Drug susceptibility. To assess nucleoside analog susceptibility, dose response assays for 
PBMC were designed to parallel current CrFK assays used in the laboratory and methods 
used by the AIDS Clinical Trials Group (39). Five million (5 x 106) con A-stimulated 
SPF feline PBMC cultured for 6 days were infected en masse at a multiplicity of infection 
(MOI) of 0.001 in a total volume of 2 ml medium for 2- 4 h. Quadruplicate replicas of 
sterile distilled water or one of five dilutions of drug were made in 2 ml of medium per 
well in a 24-well plate. Two hundred thousand (2 x 105) infected cells were then added to 
each well of the pretreated plate and incubated at 37°C in 5% C 0 2 for 7 days. One ml of 
medium was removed from each well 3.5 days postinfection and was replaced with fresh 
medium and drug. Supernatant samples were harvested on day 7 postinfection, tested for 
p24 antigen expression, replicas averaged, and data plotted as inhibitor concentration 
versus p24 gag protein production expressed as a percentage of the control value (Fig.
3.2). Drug concentration needed for 50% inhibition (IC50) of p24 gag protein production 
was determined from the linear portion of the curve using computer-generated linear 
regression as previously reported for CrFK assays (83). Experiments evaluating AZT 
(gift of Burroughs Wellcome Co., Research Triangle Park, NC), 3TC (kind gift of 
Raymond F. Schinazi, Emory University, Atlanta, GA), and 2’,3 -dideoxycytidine (ddC) 
(Sigma Chemical Co., St. Louis, MO) were done at least twice with each virus. Mean 
IC50 values of FTV-Maxam and FTV-pPPR mutants were compared to wild-type FTV- 
pPPR data using a Student’s t-test with a significance level of p < 0.05 (SPSS, Chicago, 
EL).
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Replication kinetics. In order to compare replication kinetics between different virus 
stocks, 5 x 106 SPF PBMC were adsorbed with virus at an MOI of 0.001 in 2 ml medium 
for 2 - 4 h. Three ml of medium were added for a final volume of 5 ml and a final cell 
concentration of 1 x 106 cells ml'1 in an upright T-25 culture flask. Cells were incubated 
at 37°C in 5% C 0 2. One-ml samples for RT activity determination were collected on 
days 3, 6, 8, 10, 13, and 15, and 0.3-ml samples for p24 antigen measurement were 
collected on days 1, 2, 3 ,4 , 5, 6, 8, 10, 13, and 15. RT samples were centrifuged at 
41,000 x g for 60 min at 4°C, the resulting virion pellets lysed with 15 pi detergent buffer 
as described previously (66), and samples stored along with p24 antigen samples at -80°C 
until assayed.
Reverse transcriptase. Virion RT from FTV-pPPR and FTV-p34TF10 was harvested 
from cell culture supernatants and purified using DEAE-cellulose and phosphocellulose 
(Whatman, Hillsboro, OR) column chromatography as previously described (64). Assays 
for RT activity using poly(rA)-oIigo(dT)10 or poly(rI)-oIigo(dC) template-primers 
(Pharmacia LKB, Piscataway, NJ) were done as previously reported (66). Assays were 
repeated at least twice with 3 determinations per experiment. Double reciprocal plots 
were used to determine kinetic constants (K^ and K*) as previously published (63).
Means were compared using a Student’s t-test with a significance level of p < 0.05 
(SPSS, Chicago, EL).
MOLECULAR CLONING OF MUTANT VIRUSES
An 877-bp Nco\-Bgl2 fragment, corresponding to nucleotides 2499 to 3376 of the
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parental FIV-pPPR plasmid, was cloned into Litmus-29 (New England Biolabs, Inc., 
Beverly, MA) and mutagenized with the Muta-Gene Phagemid kit (Bio-Rad Laboratories, 
Hercules, CA). Mutagenesis primers 5-TCAATATGTGGATGACA-3’and 5 - 
TCAATATACGGATGACA-3’ were used to introduce the M183V and M183T 
mutations, respectively (mutations underlined). After sequence analysis to verify the 
presence of the desired mutations, the 877-bp Nco\-Bgl2 fragment was ligated into N col- 
•Bg/2-digested FIV-pPPR and transformed into SURE-2 Supercompetent E. coli 
(Stratagene) and incubated at 32°C. The complete insert was sequenced to confirm the 
presence of desired mutations and the integrity of the remainder of the fragment. All 
sequencing was done at the Murdock Molecular Biology Center using a  Taq DyeDeoxy 
Terminator sequencing kit and a model 373A automated DNA sequencer (Applied 
Biosystems). Full-length mutated clones were transformed into the J5 strain of E. coli 
JM109 to prevent bacterial degradation of the plasmid during long-term storage and 
plasmid propagation.
Proviral mutant DNA was transfected into CrFK cells and cocultured with SPF 
feline PBMC as described for FIV-pPPR. Mutant viruses were cultured in the presence 
of 5 pM 3TC to maintain selection pressure for the introduced mutations. Viral stocks 
were titered as described for FIV-pPPR and FIV-MAXAM.
REVERSION STUDIES
The FIV-pPPR codon 183 mutants were passaged for three rounds of infection in 
SPF feline PBMC in the absence of 3TC. Viral stocks and infected PBMC were
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harvested from each passage. Viral stocks from each new round of infection were titered 
so that the subsequent round of infection was started with an MOI of 0.001. For 
consistency throughout the experiment, virus was always passaged in cells from the same 
donor, and titers were always measured in cells from the same donor. Drug susceptibility 
assays were all done in parallel in cells from one donor after virus passaging was 
completed.
Genomic DNA was isolated and purified from infected PBMC of each round of 
infection using a QIAamp tissue kit (Qiagen, Inc., Valencia, CA). Purified genomic DNA 
was used as template for PCR amplification using FTV-specific primers as described for 
FIV-MAXAM. PCR amplification products were sequenced to determine if the 
introduced mutations were present after each round o f infection.
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CHAPTER 3
MUTANTS OF PATHOGENIC FELINE IMMUNODEFICIENCY VIRUS 
RESEMBLE HOMOLOGOUS MUTANTS OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 IN 3TC RESISTANCE
INTRODUCTION
Antiretroviral drug resistance develops during treatment o f patients infected with 
human immunodeficiency virus type 1 (HIV-1) (46,60,85). The effects of drug resistance 
on the pathogenesis of HIV-1 are not known and cannot be thoroughly studied in humans 
(46,85). There is currently a need for studies in appropriate animal models to answer 
basic questions about the effects of drug resistance on Ientiviral pathogenesis (85). Data 
from such studies may provide valuable information for making better therapeutic 
decisions in the treatment of HIV-1-infected patients.
Understanding the effects of oxathiolane nucleoside analog resistance on the 
pathogenesis of lentiviruses is especially critical since (-)-P-L-2’,3-dideoxy-3 - 
thiacytidine (3TC, lamivudine) has become an important part of highly active 
antiretroviral therapy (HAART) for HIV-1 infection (9,29). A mutant virus population 
carrying a methionine-to-valine mutation at codon 184 (Ml84V) of the reverse 
transcriptase (RT)-encoding region of the pol gene characteristically arises in HIV-1- 
infected patients within weeks of starting treatment with 3TC (92). This mutation is 
interesting because it also changes pre-existing phenotypic 3 -azido-3-deoxythymidine
23
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(AZT) resistance to AZT susceptibility (48,100), enhances RT in vitro insertional fidelity 
(36,69,70,105,106), and may decrease viral replication rate (4,42,108). These changes 
could be favorable for HIV-1-infected patients if they decreased the pathogenicity of the 
mutant virus compared to wild-type virus. Another mutation of methionine-to-threonine 
(M184T) at codon 184 of HTV-1 has been selected in vitro and also confers resistance to 
3TC (42). HIV-1 codon 184 is located in the highly conserved YMDD motif of the RT- 
encoding region of the pol gene (38,45), increasing the probability that genetically similar 
mutants of other Ientiviral species may show functional homology and comparable drug 
resistance.
FTV is a lentivirus that causes an immunodeficiency syndrome in cats similar to 
that seen in HTV-1-infected humans (21,71,76,109). FIV has been used as an in vivo 
animal model for studying HIV-1 pathogenesis issues such as immunological and 
neurological abnormalities (21,33,72,76,80,109,110), vertical transmission (67), 
opportunistic infections (15,84), and cytokine dysregulation (50,52). The cell culture- 
adapted molecular clone of FTV-Petaluma, FTV-p34TF10 (97), has been used extensively 
for in vitro selection of nucleoside analog-resistant mutants (27,59,83,94,95,113). In fact, 
aFTV-p34TF10 M183T mutant, homologous to the HTV-1 M184T mutant, was selected 
in cell culture in the presence of the 3TC-related oxathiolane nucleoside analog, (-)-p-L- 
2’,3-dideoxy-5-fluoro-3-thiacytidine [(-)-FTC] (94). However, in vivo pathogenesis 
studies using drug-resistant mutants have been hindered by the inability of FIV-p34TF10 
to produce clinical disease in experimentally infected cats. The development and 
characterization of an immuno- and neuropathogenic molecular clone, FIV-pPPR (74),
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has provided a tool for studying pathogenesis and drug resistance in cats.
The purpose of the present studies was threefold. First, we compared in vitro 
replication kinetics and nucleoside analog susceptibilities of FIV-pPPR with those of a 
clinical FIV isolate to determine if the molecular clone accurately reflected the properties 
of natural FTV. Next, we characterized the nucleoside analog susceptibility and enzyme 
kinetics of purified FIV-pPPR virion RT. Finally, we engineered site-directed mutations 
homologous to codon 184 mutations of HTV-1 into the RT-encoding region of the pol 
gene of FIV-pPPR and determined the susceptibility of the resulting mutants to 3TC and 
other selected nucleoside analogs.
EXPERIMENTAL RESULTS
Virus Titering. It was necessary to propagate and store first passage viral stocks of FIV- 
pPPR, a biological FIV isolate (FTV-Maxam), and FTV-pPPR mutants in order to do 
replication studies and nucleoside analog susceptibility testing on virus allowed minimal 
time in culture for acquiring new mutations. Viral growth and titer assays using FIV- 
pPPR and FIV-MAXAM were done in the absence of drug. Titers were 8.5 x 103 
T d D 50/ml for FIV-pPPR and 5.5 x 103TCID50/ml for FTV-Maxam.
First passage viral stocks of FIV-pPPR Ml83 V and M183T mutants were 
propagated in the presence of 5 pM 3TC in order to maintain drug selection pressure and 
to assure maintenance of the alleged drug resistance mutations. This drug concentration 
was chosen because it was about 10-fold higher than the measured IC50 of wild-type vims,
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and both mutants were predicted to be about 100-fold resistant to 3TC based on data in 
the HTV-1 literature (4,42,90,91,100). Titers were 7 x 103 TCID5t/m l for M183V and 8.1 
x 102 TCIDjo/ml for M183T. Drug susceptibility assays done later would show that the 
IC50 of 3TC for the M183T mutant was actually slightly less than 5 pM. Subsequently, 
the titer of the virus stock should have been suppressed by at least 50% as a consequence 
of the relatively high drug concentration present. The corrected titer would be about 2 x 
103 T d D S0/ml.
Molecular clone compared to natural virus isolate. Next, in order to ensure that 
results of future studies would be applicable to natural FTV infection, we determined if 
the replication kinetics and nucleoside analog drug susceptibilities of the pathogenic 
molecular clone, FIV-pPPR, accurately reflected properties of a natural FTV isolate.
Curves representing RT activity of FIV-pPPR and FTV-Maxam were similar, with 
standard error bars overlapping on days 6 and 8 postinfection during the log phase of 
virus replication (Fig. 3.1). p24 antigen levels gave similar results (data not shown).
These experiments indicated that FIV-pPPR and FIV-Maxam replicated at similar rates 
and that day 7 postinfection was an appropriate endpoint for drug susceptibility assays 
since this time point occurred during the log phase of viral replication. FTV-pPPR and 
FIV-Maxam ICS0 values for AZT and ddC were similar, but the ICS0 for 3TC for FTV- 
Maxam was significantly less than that of FIV-pPPR (Table 3.1). These results 
confirmed that FTV-pPPR closely reflects the in vitro behavior of a natural FTV isolate in 
replication kinetics. Nucleoside analog susceptibilities were similar between FIV-pPPR 
and FIV-Maxam. The increased susceptibility of FIV-Maxam to 3TC may have reflected
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Figure 3.1. Replication kinetics of wild-type feline immunodeficiency virus (FIV) and 
site-directed mutants. Replication kinetics were measured by reverse transcriptase (RT) 
analysis of supernatants from specific pathogen free (SPF) feline peripheral blood 
mononuclear cells (PBMC) infected with uninfected tissue culture supernatant (sham) 
(■), wild-type pathogenic molecular clone (FIV-pPPR) ( • ) ,  natural vims isolate (FTV- 
Maxam) (▼), and codon 183 mutants [FTV-pPPR M183V (O) and FTV-pPPR M183T 
(V)]. Data from two or more experiments are graphed as mean values with error bars 
representing SEM.
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TABLE 3.1. Susceptibilities of FIV-Maxam, FIV-pPPR, and 3TC-resistant FIV-pPPR 
clones, M l83V and M183T, to selected nucleoside analogs
Compound Mean ICS0 (|iM) +/- SEMa
FTV-Maxamb FIV-pPPRc M183Vd M183T1
AZT 0.07 +/- 0.02 0.03+/-0.02 0.04+/-0.01 0.16+/-0.03
3TC 0.14+/- 0.005* 0.46 +/- 0.04 38.3 +/- 6.5* 4.83 +/- 1.02*
(-)-FTC NDe 0.18+/-0.04 49.8 +/- 19.6 2.05+/-0.15*
ddC 0.86 +/- 0.07 1.21 +/-0.56 1.04+/-0.28 2.35 +/- 0.05
a Values were determined by p24 gag protein production inhibition assays in feline 
peripheral blood mononuclear cells and represent two or more experiments with four 
determinations per experiment. 
b FIV-Maxam: natural isolate 
c FIV-pPPR: wild-type pathogenic molecular clone
d M l 83V and M183T are site-directed mutants of FIV-pPPR. The wild-type methionine 
(ATG) at codon 183 of the RT-encoding region of the pol gene was changed to valine 
(GTG) and threonine (ACG), respectively. 
e ND: not done
* Statistical significance was defined as p < 0.05 using a 2-tailed t-test (SPSS, Chicago, 
IL) comparing values for FIV-pPPR to other viruses.
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the heterogeneity of the quasispecies of the biological isolate. The dominant quasispecies 
in the population may have been more susceptible to initial 3TC treatment than the 
homogeneous FIV-pPPR viral clone. In spite of this difference, FIV-pPPR appears to be 
suitable for modeling nucleoside analog susceptibility issues of natural FIV infection in 
PBMC.
FIV-pPPR virion RT analysis. Since RT is the target of nucleoside analog inhibitors, 
the interaction of the 5 -phosphorylated form of these drags with the purified, physiologic 
form of the enzyme is important. Also, in order to use pathogenic FIV as a model for 
mechanisms of nucleoside analog resistance in HIV-1, it was important to determine how 
similar the interactions of activated drag with RT were between HIV-1 and FTV-pPPR. 
Previous work showed that the RT of a nonpathogenic molecular clone of FTV, FTV- 
p34TF10, was similar to HIV-1 RT biochemically and in nucleoside analog susceptibility 
(63). Therefore, we used purified virion RT of FIV-p34TF10 to compare to purified 
virion RT of FIV-pPPR. Kinetic values (K^ and Kj) for FIV-pPPR RT were like FIV- 
p34TF10 with two exceptions (Table 3.2). The K,,, of d'lTP was significantly less for 
FIV-pPPR compared to FIV-p34TF10. In addition, the Kj for ddCTP was significantly 
higher for FIV-pPPR than for FIV-p34TF10. These kinetic data suggest that FTV-pPPR 
RT processes the substrate, dTTP, more efficiently than the RT of FIV-p34TF10. Also, 
the RT of FIV-pPPR requires a higher concentration of ddCTP to effect enzyme 
inhibition compared to the RT of FTV-p34TF10. FIV-pPPR kinetic measurements, 
however, were similar to values previously reported for HTV-1 (63,81).
FTV-pPPR codon 183 m utants. In order to determine if FTV-pPPR codon 183 mutants
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exhibit drug resistance similar to their HIV-1 counterparts, FIV-pPPR mutants 
homologous to 3TC-resistant HIV-1 M184V and M184T mutants were cloned and 
characterized in vitro. The replication rates during the log phase of replication for FTV- 
pPPR M183V and M183T were similar to FTV-pPPR and FTV-Maxam (Fig. 3.1). While 
the magnitude of replication was slightly higher for wild-type FIV-pPPR than the other 
viruses, the initial rates were not detectably different from each other.
FIV-pPPR M l83V was highly resistant to 3TC while M183T was intermediate in 
resistance to 3TC (Fig. 3.2, Table 3.1). Both mutant viruses appeared cross-resistant to 
the related oxathiolane nucleoside, (-)-P-L-2’,3’-dideoxy-5-fluoro-3-thiacytidine [(-)- 
FTC], to similar magnitudes over wild-type levels as they were to 3TC, but there was not 
a statistically significant difference between FTV-pPPR and FIV-pPPR M183V. Variation 
of the data for FIV-pPPR Ml83V likely affected the statistical results. More 
experimental repetitions might overcome this problem. Cross-resistance to AZT or ddC 
was not detected (Table 3.1). These data showed that mutations in the conserved YMDD 
motif of FTV-pPPR RT homologous to codon 184 mutations of HTV-1 RT confer drug 
resistance to 3TC.
Mutant reversion studies. Finally, in order to study the genetic stability of the FIV- 
pPPR M l 83V and M183T mutations in the absence of drug selection pressure, mutants 
were passaged for three rounds of infection in SPF feline PBMC without 3TC present.
Both mutants remained phenotypically resistant to 3TC (30- and 4-fold for M 183V and 
M183T, respectively), but their IC50 values decreased from 38.3 to 12.2 pM forM183V 
and 4.8 to 1.6 pM for Ml83T. Sequence analysis of PCR-amplified proviral DNA from
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Figure 3.2. 3TC dose response curve of wild-type feline immunodeficiency virus (FIV) 
and site-directed mutants. 3TC inhibition of p24 gag protein production in specific 
pathogen free (SPF) feline peripheral blood mononuclear cells (PBMC) infected with 
wild-type pathogenic molecular clone (FTV-pPPR) ( • ) ,  natural virus isolate (FTV- 
Maxam) (T), and codon 183 mutants [FIV-pPPR M l83V (O) and FIV-pPPR M183T(V)] 
was measured by ELISA. Results are from two or more experiments with four 
determinations per experiment. Error bars represent SEM.
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genomic DNA extracts of infected PBMC confirmed the presence of the M 183 V and 
M183T mutations after three rounds and two rounds of infection, respectively. No 
evidence of emergence of the wild-type nucleotide sequence was demonstrated on 
sequencing chromatographs. These data suggested that FIV codon 183 mutations are 
genetically stable, but that some factor(s) outside the YMDD motif may be arising in the 
absence of selection pressure and suppressing the resistance effects of these mutations.
DISCUSSION
In summary, the FIV-pPPR M l83V mutant was comparable to its HIV-1 
homologue in magnitude of drug resistance (~ 80-fold). HIV-1 M l84V mutants showed 
100-fold or greater resistance to oxathiolane nucleosides when obtained from clinical 
patients treated with 3TC (92) or from in vitro selection using 3TC (25,91,100) or (-)- 
FTC (91). FIV-pPPR M183V also showed no cross-resistance to AZT or ddC, similar to 
results reported previously for HIV-1 M l84V (91,100) and simian immunodeficiency 
virus (SIV) (10). The functional homologies we have shown between HIV-1 Ml84V and 
FTV-pPPR Ml83V and the clinical importance of the HIV-1 Ml84V mutant make the 
FTV-pPPR Ml83V mutant a logical first choice for pathogenesis studies in 
experimentally infected cats. The FIV-pPPR M183T mutant was somewhat less resistant 
(-10-fold) to 3TC than its in vr'fro-selected HTV-1 homologue (~100-fold). This 
transversion mutation (ATG to ACG) has only been found as a result of certain in vitro 
selection protocols in both FIV (94) and HTV-1 (42); its clinical significance is not
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known.
Experiments evaluating replication kinetics showed no differences between wild- 
type FTV-pPPR and the codon 183 mutants. These findings contrasted with reported 
replication impairment and decreased viral fitness of the homologous HIV-1 mutants, 
HIV-1 M184V (4,42,108) and M184T (4,42). These observations may be explained by 
differences between the HIV-1 and FIV viruses.
Reversion studies allow multiple rounds of viral replication in the absence of 
drug. This mimics the discontinuation of drug therapy in drug-treated HIV-1-infected 
patients. Phenotypic 3TC resistance of FIV-pPPR M l83V and M183T mutants decreased 
from 80-fold to 30-fold and from 10-fold to 4-fold, respectively, after 3 rounds of 
infection in the absence of 3TC. However, there was no sequencing chromatographic 
evidence of wild-type virus emergence. This suggested that factor(s) outside the YMDD 
motif affecting phenotypic drug resistance developed during the absence of drug selection 
pressure. These factors could be the development of mutations in other viral genes or 
changes in host cell factors. Previous work on rapidly reverting AZT-resistant mutants of 
FIV-p34TF10 (83) suggested a similar explanation involving areas outside the RT- 
encoding region of the pol gene. Determining and understanding these mechanisms may 
help clarify if scheduled drug rotation therapy is warranted or reasonable.
Our present work describes a new direction for using a pathogenic molecular 
clone of FTV, FIV-pPPR, as a model for studying nucleoside analog resistance of 
lentiviruses with direct application to HIV-1. Mutations responsible for drag resistance 
in conserved sites of HIV-1 RT can be identified and homologous mutations introduced
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into FIV-pPPR. In vitro screening of the FIV mutants for drug resistance confirms 
whether functional homology exists. These mutants can then be studied in vivo to 
address questions of drug resistance effects on pathogenesis that cannot be evaluated in 
humans infected with HIV-1. Using highly conserved sites for initial mutation studies 
maximizes the likelihood that results of FIV pathogenesis studies will be applicable to 
HIV-1 treatment.
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CHAPTER 4 
FUTURE DIRECTIONS
In spite of the advances made in the treatment of human immunodeficiency virus 
type 1 (HIV-1) infection, there is still no cure. As drug resistance continues to develop 
against each new therapeutic agent, the focus of the drug industry is on developing novel 
approaches to inhibit more crucial steps in the life cycle o f Ientiviruses. Multiple drug 
therapy, for those who can afford it, will continue to be the foundation of treatment in the 
near future. As more and more different classes of drugs targeting everything from viral- 
encoded enzymes to viral regulatory proteins to RNA secondary structure are used 
simultaneously, the opportunity for drug interactions and toxicity increase. In addition, 
many questions about the basic biological mechanisms causing the observed pathogenesis 
associated with HIV-1 infection remain unanswered. Many of these issues can best be 
addressed in an animal model of natural lentiviral infection. Until there is a cure for HIV- 
1 infection, it is likely the feline immunodeficiency virus (FIV) model will continue to 
play an important role in lentiviral research.
The obvious first step after the work presented in this dissertation is to test the 
FIV-pPPR Ml83V mutant in specific pathogen free (SPF) cats. Cats infected with the 
3TC-resistant mutant and treated with drug mimic HIV-1-infected patients on drug 
therapy who have developed resistant virus. Cats infected with FIV-pPPR M l83V and 
not treated with 3TC mirror patients who have acquired drug resistance before
38
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discontinuing drug therapy. Controls would include sham-infected and parental (FIV- 
pPPR ) virus-infected groups with and without drug treatment. The purpose of this type 
of initial study is quite broad. From the sham-infected control groups, one would expect 
to leam the responses of healthy cats to testing procedures and the side effects of 3TC 
therapy in normal cats. Next, the untreated group infected with wild-type virus 
demonstrates the immunological and neurological consequences of viral infection, a 
positive control. In comparison, the wild-type virus-infected group treated with 3TC 
shows the efficacy of the drug treatment on the progression of disease and allows for the 
natural outgrowth of drag-resistant virus. Finally, the disease progression, host antiviral 
responses, viral replication, and tissue distribution of the mutant-infected groups would 
be compared to those of the wild-type virus-infected groups. Differences between these 
groups may help answer questions concerning the effects of drug resistance on viral 
replication and pathogenesis.
If pathogenic differences between wild-type and drag-resistant viruses are 
demonstrable, then continuing this line of research would be interesting and reasonable. 
The possibilities are that the mutant virus would be more pathogenic, less pathogenic, or 
the same as the wild-type parent. Studies would focus on the question of how the 
difference in virus genetics could account for those differences seen at the animal level. 
Tissue tropism, level of virus sequestration in tissue, viral replication, plasma viral load, 
functional immune capacity, and neurologic parameters may all be helpful in deciphering 
how variation occurs between parental and mutant viruses (5,15,16,73). In addition, the 
pharmacology of 3TC in the cat would need to be completely understood in order to
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understand the drug selection pressure being applied to virus in various tissue types and 
how this may influence the development of drug resistance or reversion to a drug- 
susceptible state. On the other hand, if no detectable differences between FIV-pPPR- and 
FIV-pPPR M183V-infected cats were present, then the primary experimental question 
would return to how to more effectively and protractedly suppress viral replication, 
regardless of drug-resistance phenotype.
Another important question of drug resistance that should be answered in the FTV 
system is that of whether the M183V mutation introduced into an AZT-resistant clone can 
reverse AZT resistance to AZT sensitivity. This is one of the intriguing aspects of the 
M l84V mutation in HIV-1. This experimental question could be approached in two 
different ways. It is possible that AZT-resistant FIV could be constructed by introducing 
the point mutation at codon 202 previously reported to confer AZT resistance on the 
nonpathogenic FIV molecular clone, FIV-p34TF10 (83). It is presently not known if this 
mutation confers AZT resistance in a pathogenic molecular clone of FIV. An alternative 
approach that mirrors HIV-1 more closely would be to introduce point mutations 
homologous to those seen in AZT-resistant HIV-1 in a  step-wise fashion into a 
pathogenic FIV clone. In either case, once an AZT-resistant mutant was developed, the 
M l83V mutation could be introduced into this (or these) clone(s) and the phenotypic drug 
susceptibility profile determined. Suppression of AZT resistance would further support 
FIV as an animal model for studying HIV-1 drug resistance issues.
In the area of new drug development, the FTV model may be useful for initial 
studies in animals. While cats have a clinical reputation for unusual drug metabolism,
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drugs that are nontoxic for cats are generally also nontoxic for humans. This rule of 
thumb, however, does not always work in the opposite direction, so some drugs available 
for treatment of humans may not be workable in the FIV model. With new protease 
inhibitors effective against FIV, HIV, and simian immunodeficiency virus (SIV) in vitro 
(51), the possibility for studying highly active antiretroviral therapy (HAART) in the 
feline model now exists. Other new therapies being developed include integrase 
inhibitors, cell binding and entry inhibitors, rev and tat inhibitors, ribozymes, antisense 
oligonucleotides, and intracellular inhibitory antibodies (20). Any o f these modalities 
could be studied for effectiveness in the FIV model. Cats are particularly manageable for 
these types of studies because of their small size, and yet they are large enough for easy 
placement of central venous or arterial catheters needed occasionally for monitoring, 
sampling, or drug administration procedures.
In addition to drug studies, the FIV model can be used to answer questions about 
the basic biology of lentiviral pathogenesis. Cats are of sufficient size to allow for 
sophisticated longitudinal measurements of neurological disease by electrodiagnostic 
methods as well as neurologic metabolic testing. Cats can also be behaviorally tested 
(78;96) and trained for sleep (80)and cognitive testing (96). Serial cerebrospinal fluid 
(CSF) and blood samples can be reasonably obtained, and brain regions can be identified 
electrodiagnostically as well as histopathologically. This provides ample measurements 
for following disease progression long-term. With the availability o f two pathogenic 
molecular clones of FIV in the United States that appear to have different tropisms and 
clinical manifestations (immunopathogenesis versus neuropathogenesis), molecular
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virology studies evaluating the genetic basis of these differences are now possible. 
Specialized studies of viral distribution in the brain, presence or absence of neuronal 
injury, antiretroviral drug distribution in the nervous system, and the effects of viral 
infection on excitatory neurotransmitter metabolism can all be studied as well.
hi conclusion, the work presented in this dissertation is the basis for beginning 
molecular virology studies of nucleoside analog drug resistance using the FIV model in 
cats. This is only a very limited aspect, however, of what is possible to do with this 
experimental system. Basic pathophysiology, neuropharmacology, toxicology, viral 
replication, and tissue tropism are all candidates for future experiments using FTV in cats.
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MAPPING IN  VIVO REPLICATION AND PATHOGENESIS DETERMINANTS 
OF ALEUTIAN MINK DISEASE PARVOVIRUS
CHAPTER 5 
INTRODUCTION
PARVOVIRUSES
Genomic organization. The autonomous parvoviruses are recognized as the etiologic 
agents of a variety of important diseases affecting many vertebrate animals, including 
mice, rats, cats, mink, dogs, pigs, cows, and man (126,133,158,181,212). Parvoviruses 
are small, nonenveloped icosahedral viruses with linear, single-stranded 
deoxyribonucleotide (DNA) genomes approximately 5000 nucleotides in length (158). 
All contain palindromic sequences at the 5’ and 3’ termini of the genome that form 
secondary hairpin structures necessary for parvoviral replication (127,153,190,208-211). 
These small genomes contain two major open reading frames (ORFs). The left ORF is 
controlled by a promoter at ~ 4 map units (MU) and specifies at least one nonstructural 
(NS) protein necessary for viral replication and gene regulation
(132,145,157,176,202,203,209,214,215). The promoter for the right ORF is located at -  
38 to 40 MU. The right ORF encodes overlapping sequences of at least two structural, or 
capsid (VP), proteins (132,140,144,158,183,193,203).
Nonstructural proteins. Parvovirus progeny do not bud from the host cell surface like
43
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retroviruses. Instead, host cell lysis releases newly generated virions into the surrounding 
environment. Although the exact effectors remain obscure, evidence suggests that the 
nonstructural proteins are integrally involved in this presumably cytotoxic mechanism 
(147,184,186,192,201). Subsequently, the nonstructural proteins may be important in 
determining the efficiency of viral spread through the infected host as well as in cell 
culture systems.
The largest of the nonstructural proteins, NS1, has several biochemical properties 
necessary for replication and gene regulation. NS1 shows ATP-binding, ATPase, 
helicase, site-specific endonuclease, and covalent and non-covalent DNA-binding 
properties (156,222). The carboxy-terminus of the NS1 protein contains a transcription- 
activating domain (182,185) and is thought to rr<my-activate the P38 promoter that 
controls transcription of the capsid genes (158,162,182,185). Therefore, NS1 may be 
able to influence the efficiency of viral replication and new virion formation as well as 
virion release from cells.
Structural (capsid) proteins. Structural proteins of parvoviruses are the building blocks 
of the capsid that encloses the viral genome. VP1 and VP2 are formed by alternate 
splicing of the messenger RNA transcribed from the right ORF (176). VP1 contains the 
complete sequence of VP2 and an additional amino-terminal domain that varies in size 
among parvoviruses (116). VP3, in parvoviruses that have a third capsid protein, is a 
proteolytic product of VP2 formed after virion assembly (116).
The number of capsid protein species per virion is a distinguishing feature of each 
parvovirus. These polypeptides all have a similar eight-stranded anti-parallel P-barrel
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motif that contains about one-third of the amino acid content of each protein. The P- 
barrel motif lies below the capsid surface while the remaining two-thirds of the 
polypeptide structure is made up of surface loops, inserted between the P strands (116). 
These surface loops have the amino acid residues comprising cell receptors and antigenic 
epitopes (116). Small numbers of amino acid changes in these surface loops can 
dramatically alter biological properties of the parvoviruses, such as the host ranges of 
canine parvovirus (CPV) and feline panleukopenia (FPV). CPV and FPV are 98% 
identical. However, three amino acid differences in the capsid protein allow CPV to 
replicate in canine cells whereas FPV cannot (115).
Clinical disease. The clinical signs associated with acute parvoviral infection are usually 
related to the site of viral replication. Target cells are typically those whose biology 
requires rapid cell replication and turnover. For instance, FPV and CPV both infect small 
intestinal crypt cells, the cell population responsible for replenishing the epithelium of 
intestinal villi (169). Clinical signs generally include severe, and often bloody, diarrhea. 
Human parvovirus B19 selectively infects red blood cell progenitors in the bone marrow 
(161). Severe aplastic crises can be a clinical result.
The S phase of the cell cycle appears to be required for efficient parvoviral 
replication (158). Host cell replication and the availability of host cell machinery is 
necessary for the intracellular replication of parvoviruses that have so few viral-encoded 
accessory proteins. Subsequently, parvoviral infection is common in young animals and 
children. The strict cellular requirements for replication limit the spectrum of target cells 
for parvoviruses, particularly in adult animals (219).
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ALEUTIAN MINK DISEASE PARVOVIRUS
Host factors. Aleutian mink disease was first described in mutant mink homozygous for 
a recessive dilute coat color gene (Aleutian gene) in the 1940s (167). The fur of these 
mink, called sapphire color-phase, was gun-metal gray in contrast to the darker and richer 
fur colors typical of mink of other color phases, such as pastel. Aleutian mink were noted 
to be highly susceptible to a chronic wasting disease later determined to be a parvovirus 
(143). In addition to the unusual coloration, immune dysfunction was mapped to the 
Aleutian gene. The genetic immune disorder is referred to as Chediak-Higashi syndrome, 
characterized by oculocutaneous albinism, recurrent pyogenic infections, platelet 
dysfunction, and enlarged granules in granulocytic blood cells and tissue mast cells (130). 
More specifically, immune dysfunction may include decreased fusion of lysosomes with 
phagosomes, decreased bactericidal capacity, decreased chemotaxis, defective natural 
killer cell function (148), nucleotide pool deficits in platelets (130,131), and serotonin 
storage dysfunction of platelets (130). Therefore, host factors are certainly important in 
the study of Aleutian mink disease parvovirus (ADV). Aleutian genotype mink are often 
used for experimental study since they develop disease rapidly and consistently when 
infected with pathogenic strains of virus (164).
Clinical disease-adults. Classical Aleutian disease (AD) of adult mink is characterized 
by chronic, progressive w'asting, widespread proliferation of plasma cells and 
lymphocytes, hypergammaglobulinemia, glomerulonephritis (164), and necrotizing 
arteritis, particularly of the bladder and stomach walls (Dr. William J. Hadlow, personal 
communication) and brain. These abnormalities are a result of circulating antigen-
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antibody immune complexes and their deposition in small capillary beds (205). 
Plasmacytic, lymphocytic infiltrates of the liver can be severe enough to destroy the 
normal architecture of the liver lobules (unpublished data), and the medullary cords of the 
mesenteric lymph node can be dramatically thickened, primarily by plasma cells.
Aleutian genotype mink infected with highly pathogenic virus strains, such as 
ADV-Utah 1, are usually viremic by 10 days postinfection and remain persistently 
infected (138,166). Infection of adults is believed to be a restricted infection of 
mononuclear immune cells (118,135,142,204) and may be enhanced, rather than 
neutralized, by antiviral antibodies (114,163,177-179). Disease usually progresses 
quickly over 60 to 90 days (138,166), and clinical illness appears to be the result of renal 
failure, likely a result of severe glomerulonephritis (164) and possibly additional 
destructive renal tubular lesions (194). Mink of other color phases, such as royal pastel, 
respond to pathogenic virus strains erratically, even when inoculated with large numbers 
of virus (164). Sometimes only half of royal pastels become clinically affected by 
experimental infection, and many of these mink have a more protracted course than 
sapphire (Aleutian) mink (164).
Clinical disease-kits. Aleutian mink kits bom to seronegative dams and infected 
perinatally with ADV-Utah 1 succumb rapidly to a fulminant interstitial pneumonia that 
causes severe respiratory distress and death by two to six weeks of age (118,119,121).
ADV replicates permissively in type BE pneumocytes of the lung and destroys surfactant 
production by these cells (118,119,121). A  detectable antibody response is not generated 
by neonatal mink kits (117).
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Disease variability. While highly pathogenic strains of ADV cause a predictably severe 
disease, milder forms of the adult and neonatal diseases have been described 
(122,139,171). In addition, inapparent, or subclinical, forms of ADV have been reported 
(123-125). ADV-G, a molecular clone derived from a cell culture-adapted isolate of 
ADV-Utah 1 (134), is nonpathogenic for adult sapphire mink and only mildly pathogenic 
for mink kits (122,143,197). Other ADV isolates are intermediate in pathogenicity 
between ADV-G and ADV-Utah 1 (171,172). Subsequendy, a broad range of disease 
severity for which host factors do not appear to account is seen among various ADV 
isolates.
Viral factors. In addition to the differences in disease severity between ADV-G and 
ADV-Utah 1, there are also variations in cell tropism. ADV-G replicates permissively 
and to high titers in Crandell feline kidney (CrFK) cells in vitro even though it does not 
replicate in vivo (121). In contrast, ADV-Utah 1 cannot be propagated in CrFK cells but 
replicates efficiently in vivo (121,173). These replication and pathogenesis differences 
suggest regulation by viral determinants (138,139,143,197).
Previous work by Bloom, et.al., involved dissecting the ADV genome in order to 
identify possible viral determinants of in vitro and in vivo replication and pathogenesis 
(136-138,166). A region of the capsid gene was identified as encoding a minimal in vivo 
replication determinant (138). The contributions of four individual amino acids within 
that region and one additional upstream amino acid were also studied in mink (166). Two 
amino acids that differ between ADV-G and ADV-Utah 1, encoded by codons 352 and 
534 of the VP2 gene, were determined to likely participate interactively in governing in
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vivo replication (166). The nonstructural gene of ADV does not appear to affect in vivo 
replication and pathogenesis alone (137), but its interactive relationship with crucial 
capsid amino acids has not been determined.
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CHAPTER 6 
MATERIALS AND METHODS
MOLECULAR CLONING OF CHIM ERIC VIRUSES
Plasmid vectors. Standard molecular biology techniques were used for all cloning 
(134,136,197). The full-length parent ADV molecular clones ADV-G (XXXI-K-11-15) 
(137), ADV-G/U-8 (XXIX-A-12), and ADV-G/U-10 (XXX-J-8-10) (138) were reported 
previously (Figure 7.1). In order to construct the new clones ADV-G/U-13 (29STG) and 
ADV-G/U-14 (29STJ8) (Figure 7.1, Table 7.1), the previously described pIC4-2 plasmid 
(166) was modified by replacing its 1.3 kb BamHUXhol ADV-G sequence fragment with 
the corresponding fragment from ADV-G/U-8 that contained three coding (Table 7.1) and 
one non-coding (T to C at nucleotide 820 of NS1) ADV-Utah 1 nucleotide changes in the 
NS1 gene. This new plasmid was designated 29ST. The presence of the correct insert 
was verified by restriction enzyme digestion with Seal. Plasmids receiving the ADV- 
Utah 1 NS1 segment contained two Seal restriction sites, whereas parental pIC4-2 
plasmids contained three Seal sites. Digestion of these plasmids resulted in two and three 
fragments, respectively, when visualized on 0.7% agarose gels. The plasmids pIC4-2 and 
29ST were maintained in E. coli JM109.
Construction of full-length chimeras. The downstream EcoKV/HindlB. 156-bp cassette 
from pBR322 (previously engineered into the pIC4-2 plasmid) was removed from 29ST 
by restriction enzyme digestion and replaced with a similarly digested, but approximately 
1-kb in size, fragment from ADV-G to construct ADV-G/U-13 and from ADV-G/U-10 to
50
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construct ADV-G/U-I4 (Figure 7.1). Full-length clones containing the correct inserts 
were larger than the unaltered acceptor plasmid by about 0.9 kb. This was easily 
demonstrated on 0.7% agarose gels after EcoRV/HindlH. digestion of ligation reaction 
transformants. ADV-G/U-15 (Figure 7.1) was made by replacing the EcoRV/HindUl 
fragment of pIC4-2 with that of ADV-G/U-8. Screening for plasmids carrying the correct 
inserts was done as described for ADV-G/U-13 and -14.
Full-length molecular clones were transformed by electroporation and were 
amplified in Escherichia coli JC8111 (recBCsbcrecF) (134,146). This bacterial strain 
was required to reduce the degradation of the unstable parvoviral genomic right-hand 
hairpin that is necessary for parvovirus replication. Plasmid DNA was purified with a 
Wizard Maxi-prep kit (Promega, Madison, WI) and screened by restriction enzyme 
digestion for the presence of the unstable right-hand hairpin. Digestion with EcoRUBglB. 
resulted in the removal of a 2-kb fragment when the hairpin was present.
CELLS AND VIRUSES
Cells. Crandell feline kidney (CrFK) cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) as previously described (134,137).
Viruses. CrFK cells in 6-well trays were transfected with 400 ng plasmid DNA of ADV- 
G or chimeric viruses per well using Effectene (Qiagen, Santa Clarita, CA) and were 
cultured at 31.8°C for 5 days. Virus propagation through three additional cell culture 
passages was done as previously described (137). Final passage supernatants were 
collected after cell disruption and centrifugation as previously reported (137,166). Virus-
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containing supernatants were filtered through 0.45 pm filters, aliquoted, and stored at - 
20°C. Virus titers were determined by immunofluorescent assay (IFA) using fluorescein- 
conjugated polyclonal mink antiserum (137).
In vivo propagation of ADV-Utah 1 in mink kits and titer assays in adult mink 
have been reported previously (197).
ANIMALS AND INFECTION
Animals. The Rocky Mountain Laboratory animal research facilities were fully 
accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC). All procedures involving animals were approved by the Rocky 
Mountain Laboratory Animal Care and Use Committee.
Mink used in these experiments were 8-month-old female mink (Mustela vison) of 
the Aleutian phenotype obtained from an ADV-free mink ranch. Mink were housed in 
stainless steel modified primate cages in open-sided sheds as previously described (197). 
Blood samples were collected by aseptic jugular venipuncture under ketamine- 
acepromazine anesthesia at 0, 10, 30, 60, 90, and 120 days post infection (dpi). Serum 
was separated from blood cells by centrifugation and stored at -20°C.
Infection. 2 x 104 fluorescence-forming units (FFU) of chimeric viruses in a volume of 1 
ml were injected intraperitoneally (IP) into groups of four mink each. A mock-infected 
group was injected with 1 ml of supernatant collected from CrFK cells that were mock- 
transfected and passaged three additional times in cell culture. A positive control group 
received 2 x 104 mink infectious doses of ADV-Utah 1.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
53
IN  VIVO INFECTTVTTY AND PATHOGENESIS
Antibody and viremia. Antibody responses and viremia were determined at each blood 
collection time point. The antiviral antibody response to ADV infection was measured by 
C E P  using a commercial ADV antigen (United Vaccines, Madison, WI) (141,142). 
Viremia was detected using serum-based PCR using ADV-specific primers designed to 
amplify a 692-bp fragment in the VP2 region of the ADV-G genome (141,197). Prior to 
infection, sera from all mink tested negative for anti-ADV antibodies and for ADV- 
specific viral DNA amplification by PCR.
Gamma globulin measurement. At the experimental endpoint (clinical illness for 
ADV-Utah 1-infected mink and 120 dpi for all other groups), blood samples were 
collected and tissues for histopathological examination were harvested. Gamma globulin 
levels were measured in baseline and final serum samples by serum protein 
electrophoresis using a horizontal thin-layer agarose gel system (Helena Laboratories, 
Beaumont, TX). The percent contribution of gamma globulins to total serum protein was 
determined by laser densitometry and integration of the area under the curve (142,164). 
The differences between the percentage of gamma globulins in baseline and final samples 
were calculated.
Histopathology. At necropsy, tissue samples from the left lateral lobe of the liver, tail of 
the spleen, left kidney, and mesenteric lymph node were processed in a standard manner 
for hematoxylin and eosin-stained paraffin-embedded sections (164,170). Sections were 
reviewed by a board-certified veterinary pathologist (WJH) without knowledge of their 
origin.
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CLINICAL MONITORING
Physical examination parameters. All mink were monitored for body weight, rectal 
temperature, heart rate, respiratory rate, hydration status estimate, coat condition, and 
clinically evident disease at 0, 10, 30, 60, 90, and 120 dpi.
Bloodwork. Complete blood counts (CBC), platelet counts, and serum biochemistries 
were measured on 0, 60, and 120 dpi. Whole blood samples for CBC and platelet counts 
were collected into ethylenediaminetetraacetic acid-treated (EDTA) microtainer tubes 
(Becton-Dickinson, Franklin Lakes, NJ). Blood smears for cytologic examination were 
made on clean glass microscope slides from EDTA-treated blood samples within four 
hours of blood collection. Serum for biochemical analysis was separated from blood cells 
in a clot activator vacuum tube (Becton-Dickinson, Franklin Lakes, NJ) with a gelatin 
separator. Samples were shipped directly to a commercial laboratory (Pathology 
Associates Medical Laboratory, Spokane, WA) the day of collection.
Urine specific gravity and DNA isolation from urine. Urine samples were collected at 
0, 60, and 120 dpi for measurement of urine specific gravity (USPG). USPG was 
evaluated using a manual clinical reffactometer.
Urine samples were also collected at 0, 10, 30, and 60 dpi for screening for the 
presence of viral DNA. In a second unrelated study, urine was collected 14, 28, and 43 
dpi from two mink from each of three control groups, including ADV-Utah 1, ADV-G, 
and mock. DNA extraction from urine samples was done by 30% polyethylene glycol in 
3 M sodium chloride precipitation as reported by Behzadbehbahani, et. al. (129), and by 
using a Viral RNA Mini Kit (Qiagen, Valencia, CA) as directed by the company to
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remove PCR inhibitors commonly found in urine (129,165,175). Purified DNA samples 
were used as template (2.5 pi) in an ADV-specific PCR amplification reaction using 
primers to amplify a 692-bp fragment o f ADV-G VP2. PCR reaction products were 
analyzed on a 2.5% agarose gel and compared to dilutions of ADV virion standards that 
had also been processed through the Viral RNA Mini-kit.
M ink infection with filtered urine. Four sapphire mink were injected IP with 1.5 ml of 
0.45 pm-filtered urine from 30 or 60 dpi samples from mink 5716 or 5717 (ADV-Utah 1- 
infected mink). Two additional mink were injected IP with similarly processed samples 
from mock-infected mink collected at 60 dpi. These mink were monitored for the 
production of antiviral antibody titers and viremia as described above. The experimental 
endpoint was determined to be the onset of clinical signs at which time serum 
electrophoresis for gamma globulin evaluation and gross and microscopic pathological 
examinations will be done.
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CHAPTER 7
INTERACTION OF CAPSID AND NONSTRUCTURAL PROTEINS IN IN  VIVO  
REPLICATION AND PATHOGENESIS OF ADV
INTRODUCTION
Aleutian disease virus (ADV) is an autonomous parvovirus that causes disease in 
mink (Mustela vison) quite different from that caused by parvoviruses in other species. 
Infection of mink kits with virulent biological isolates such as ADV-Utah 1 results in 
fatal interstitial pneumonia in almost 100% of affected kits by two to six weeks of age 
(118,119,121). Adult infection is characterized by a protracted clinical course of viremia, 
hypergammaglobulinemia, immune complex disease, and plasmacytic, lymphocytic 
infiltration of lymphoid tissue, spleen, liver, and kidney (164). ADV-G, a molecular 
clone derived from cell culture-adapted ADV-Utah 1, is nonpathogenic for adult mink 
and only mildly pathogenic for mink kits of the susceptible Aleutian phenotype (134). 
Interestingly, sequence alignment of approximately 75% of the total genome of these two 
ADV isolates shows 97.5% identity at the nucleotide level (137,168).
Evidence from other parvovirus systems supports the ability of seemingly minor 
nucleotide sequence differences to be associated with profound biological variances. For 
instance, small differences in the capsid genes are responsible for host range variants of 
the minute vims of mice (MVM). MVM has two serologically indistinguishable types, 
MVM(p) and MVM(i), that are 97% identical in nucleotide sequence (128). However,
56
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two capsid amino acid differences allow MVM(p) to productively infect mouse 
fibroblasts and MVM(i) to infect mouse T lymphocytes (128). In addition, no more than 
three amino acid changes in the capsid gene are necessary for changing the host ranges of 
canine parvovirus (CPV) and feline panleukopenia virus (FPV) although these viruses are 
98% identical (151,217,218). Alternatively, small changes in the nonstructural proteins 
may also correlate with significant biological differences (149,195,220). Porcine 
parvovirus (PPV) host range is affected by one amino acid residue in both the 
nonstructural and capsid genes (220). Also, at least one change in the nonstructural gene 
of MVM is associated with an increase in replication efficiency in fibroblasts (195). 
Therefore, precedents in other parvoviral systems suggest that either capsid or 
nonstructural proteins, or both, may be involved in controlling in vivo replication and 
pathogenesis of ADV.
Determinants of tropism of ADV for growth in Crandell feline kidney (CrFK) 
cells and for replication of ADV in mink have been mapped to the capsid gene (137). It 
is possible that determinants of pathogenesis may reside there as well. Alternatively, 
changes in the nonstructural gene may affect pathogenesis. Supporting this possibility is 
the high degree of variability between the amino acid sequences of the NS1 proteins of 
several ADV isolates. More variability is seen between ADV isolates than is seen 
between the NS1 proteins of FPV, CPV, and mink enteritis vims (MEV) (168). In fact, 
the ratio of synonymous to non-synonymous substitutions between ADV-G and ADV- 
Utah 1 was 0.42, suggesting a positive selection for variation in the NS 1 protein may be 
occurring between these two isolates (168). It is possible that some of these changes may
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be responsible for the differences in in vivo replication and pathogenicity between these 
two types of ADV.
Recent studies in our laboratory have been defining the molecular basis of in vivo 
replication and pathogenesis of ADV by comparing chimeric viruses of ADV-Utah 1 and 
ADV-G. Two chimeras capable of replication in both cell culture and adult Aleutian 
mink and competent to cause varying degrees of disease in infected mink were recently 
reported (138). ADV-G/U-8 induced higher antiviral antibody titers and more severe 
histopathologic lesions in tissues of infected mink than ADV-G/U-10 (138). These 
chimeras differed by only four amino acids. ADV-G/U-8 contained one additional capsid 
and three additional nonstructural protein amino acid changes compared to ADV-G/U-10 
(Figure 7.1, Table 7.1). The purpose of the current study was to determine whether the 
ADV-Utah 1 amino acid changes in the capsid protein or the nonstructural protein in 
ADV-G/U-8 were responsible for its increased in vivo replication and pathogenicity 
compared to ADV-G/U-10.
RESULTS
Development of ADV chimeras. In order to compare chimeras with identical capsids 
differing only by a short segment of the nonstructural protein and vice versa, three ADV 
clones were constructed complimentary to ADV-G (ADV-G/U-13), ADV-G/U-10 (ADV- 
G/U-14), and ADV-G/U-8 (ADV-G/U-15) (Figure 7.1). This set of three pairs of viruses 
allowed comparison of the contributions of both ADV-Utah 1 NS 1 and VP2 changes in in
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Figure 7.1. Genetic structure of Aleutian mink disease virus (ADV) chimeras and in vitro 
titers. Genomic organization of chimeras between nonpathogenic ADV-G and highly 
virulent ADV-Utah 1 is shown. Sections with white background represent ADV-G 
sequence, and black sections illustrate segments of ADV-Utah 1 sequence. White 
numbers represent amino acid differences between ADV-Utah 1 and ADV-G. See Table 
7.1 for nucleotide substitutions and coding amino acid changes in NS 1 (upstream) and 
VP2 (downstream) genes and proteins, respectively. Virus titers were determined by 
immunofluorescent assay (IFA) in Crandell feline kidney (CrFK) cells.
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vivo replication and pathogenesis. ADV-G and ADV-G/U-13 both contained a complete 
ADV-G VP2 gene without and with three ADV-Utah 1 N S1 amino acid changes, 
respectively (Figure 7.1, Table 7.1). ADV-G/U-10 and ADV-G/U-14 both encoded four 
ADV-Utah 1 VP2 amino acid changes previously shown to be the minimal replication 
determinant for in vivo replication (138) without and with the short ADV-Utah 1 NS 1 
segment, respectively (Figure 7.1, Table 7.1). Finally, ADV-G/U-15 and ADV-G/U-8 
capsids both included a fifth ADV-Utah 1 amino acid change, an isoleucine to valine at 
codon 352 of VP2, without and with the ADV-Utah 1 NS 1 amino acid changes, 
respectively (Figure 7.1, Table 7.1).
Full-length ADV chimeras were transfected into CrFK cells as described in 
materials and methods. All clones replicated through four passages in cell culture, but 
there was a trend toward lower titers as more ADV-Utah 1 amino acid changes were 
present (Figure 7.1).
To assess the ability of ADV-Utah 1 to replicate in vitro, ADV-Utah 1 virus was 
used to infect CrFK cells and was passaged four times in cell culture. ADV-Utah 1 vims 
was used since a full-length ADV-Utah 1 molecular clone has not yet been developed. 
There were no positive cells detectable by IFA (Figure 7.1). These data confirmed 
previous data from our laboratory that highly pathogenic ADV-Utah 1 cannot be serially 
propagated in CrFK cells in vitro. This finding correlated with the trend toward lower in 
vitro titers as chimeras gained more ADV-Utah 1 amino acids. In fact, it suggested that 
there may be a limit to which molecular virology will be able to define in vivo replication 
and pathogenesis determinants of ADV until a cell line capable of propagating fully
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TABLE 7.1. Nucleotide and encoded amino acid differences between ADV-G and 
ADV-Utah 1 in the NS1 and VP2 gene regions involved in chimera constructions.
Gene #* Nucleotide ADV-G ADV-Utah 1 Codon ADV-G ADV-Utah 1
NS1
1 758 A G 185 Be Val
ncb 820 T C 205 Asn Asn
2 1182 G A 326 Ser Asn
3 1339 T G 378 Be Met
1 3459 A G 352 Be Val
2 3590 C G 395 His Gin
VP2 3 3705 A C 434 Asn His
4 3876, 3878 A, C G, G 491 Asn Glu
5 4005 c G 534 His Asp
a Numbers in each gene region correlate with the numbers indicating amino acid 
differences in Figure 1.
b nc represents a non-coding change that deletes a polyadenylation site from ADV-G 
(136)
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pathogenic virus is discovered.
Antiviral antibody response. In order to evaluate the immune response of mink to the 
ADV chimeras and control preparations, anti-ADV antibody was assayed on 0, 10, 30,
60, 90, and 120 dpi by CIEP. The model of consistent response was ADV-Utah 1 (Figure 
7.2). All ADV-Utah 1-infected mink surviving to 60 dpi developed titers of 1:4096. 
Mock-infected mink were negative at all time points. Mink infected with ADV-G and 
ADV-G/U-13 were all 1:16 or lower throughout the study (Figure 7.2), indicating that the 
three amino acid changes in NS 1 alone cannot alter in vivo ADV antibody responses. All 
other chimeras were associated with moderate to high antibody levels (approximately 
1:64 to 1:4096) (Figure 7.2). When evaluated using a nonparametric Wilcoxon t-test, a 
significant difference (p < 0.05) was detected between the antibody titers of the G/U-8 
and G/U-15 groups compared to G/U-14 at 120 dpi. This data demonstrated a clear 
difference between the chimeras having five capsid amino acid changes and one having 
only four. It is possible that the antibody titers of the G/U-14-infected mink were 
declining more rapidly than those of the five capsid change chimera-infected mink.
Graphs of the raw data for antibody titers showed a trend toward less variation between 
animals within groups when the ADV-Utah 1 NS 1 changes were present in the clone 
(Figure 7.2, ADV-G/U-14 and ADV-G/U-8). This suggested that NS 1 may play a role in 
making host responses to the vims more predictable and consistent, essentially making 
the vims more ADV-Utah 1-like.
These antiviral antibody titers were reevaluated by calculating the geometric mean 
titers (GMT) for each group at each time point and the reciprocal means graphed (Figure
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Figure 7.2. ADV-specific antibody titers and viremia in control and ADV chimera- 
infected mink. Each circle represents one mink at each time point indicated. There were 
four mink in each group. One mink in the ADV-G group died of causes unrelated to 
Aleutian disease, and one mink in the ADV-Utah 1 group died of undetermined causes 
between days 30 and 60 postinfection. Open circles indicate reciprocal antiviral antibody 
titers of non-viremic mink as measured by counterimmunoelectrophoresis (CIEP). Solid 
circles show the reciprocal antibody titers of mink that were concurrently viremic as 
determined by an ADV-specific PCR reaction using serum as template. Viremia was 
detected in four of four (ADV-Utah 1), three of four (ADV-G/U-8), two of four (ADV- 
G/U-10 and ADV-G/U-14), and one of four (ADV-G/U-13) mink in groups infected with 
pathogenic viruses.
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7.3). The highest final reciprocal GMT was 4074 for the ADV-Utah 1 group. A trend 
toward higher titers when five VP2 changes were present [ADV-G/U-15 (1445.4) and 
ADV-G/U-8 (1023.3)] rather than four [ADV-G/U-10 (255.6) and ADV-G/U-14 (128.8)] 
was seen. These data were similar to those found for raw antiviral antibody titers. 
Viremia. To determine if viral replication was occurring at sufficiently high levels to be 
detected systemically, serum samples were used as template for an ADV-specific PCR 
reaction on 0, 10, 30, 60, 90, and 120 dpi. Solid circles (Figure 7.2) indicated mink 
whose serum tested positive by PCR. All ADV-Utah 1-infected mink were persistently 
viremic from 10 dpi throughout the study. There were no positive samples at any time 
point for mink infected with mock, ADV-G, or ADV-G/U-13 (Figure 7.2). Two of four 
mink infected with ADV-G/U-10 were detectably viremic until 60 and 90 dpi, 
respectively. One of four mink infected with ADV-G/U-14, differing from ADV-G/U-10 
by three NS1 amino acid changes, was transiently viremic at 10 dpi. For viral constructs 
containing five capsid amino acid changes, two of four mink infected with ADV-G/U-15 
were persistently viremic throughout the study. The addition of the three ADV-Utah 1 
NS 1 amino acid changes to the five capsid changes, ADV-G/U-8, was associated with 
detectable viremia in three of four mink in the group. Two of these mink were 
transiently viremic at 10 dpi while one became viremic at 90 dpi and remained viremic 
until the end of the experiment. These data showed that the addition of the ADV-Utah 1 
NS 1 segment alone was not sufficient for in vivo replication. However, the new chimeras 
containing four and five capsid amino acid changes, ADV-G/U-14 and ADV-G/U-15, 
were capable of replicating in mink. A clear difference between chimeras ADV-G/U-8, -
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Figure 7.3. Geometric mean antibody titers (GMT) in control and ADV chimera-infected 
mink. The mean GMT for each group was calculated and its reciprocal graphed. Error 
bars represent standard error of the mean (SEM). Symbols represent chimeras as 
indicated in the upper left comer of the graph. A statistically significant difference (p = 
0.01) between ADV-G/U-8 and ADV-G/U-14 (differ by only a valine at codon 352 of 
VP2 in ADV-G/U-8) at 90 days postinfection was detected using a paired Student’s t-test. 
Final reciprocal mean GMT titers were 4074 (ADV-Utah 1), 1445.4 (ADV-G/U-15),
1023.3 (ADV-G/U-8), 255.6 (ADV-G/U-10), 128.8 (ADV-G/U-14), 1.6 (ADV-G), and 
1.4 (ADV-G/U-13).
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10, and -15 could not be established based on the incidence of viremia. However, the 
ADV-G/U-14-infected group had only one viremic mink while the ADV-G/U-8-infected 
group had three. These data correlated with the differences seen between these two 
groups in antiviral antibody production and supported the conclusion that V352 of VP2 
may influence in vivo replication.
Hypergammaglobulinemia. The development of serum hypergammaglobulinemia is a 
classic sign of progressive Aleutian disease (AD) and usually correlates with the presence 
of histopathologic lesions in tissue sections (164). The ADV-Utah 1-infected group 
showed the greatest increase in gamma globulins with the smallest error (23.5 +/- 1.1), 
indicating a highly consistent response among mink (Table 7.2). Mink infected with 
either clone containing five ADV-Utah I VP2 amino acid changes (ADV-G/U-8 or ADV- 
G/U-15) also showed the large increases in gamma globulins (16.4 and 19.2, respectively) 
(Table 7.2). ADV-G/U-10-infected mink showed a moderate increase of 9.8. These data 
showed that when valine is present at codon 352 of VP2 in conjunction with the other 
four ADV-Utah 1 capsid amino acid changes, a marked hypergammaglobulinemia 
occurred. Three ADV-Utah 1 amino acid changes in the NS 1 gene did not enhance this 
hypergammaglobulinemia.
Histopathology. Paraffin-embedded tissue sections of the liver, spleen, kidney, and 
mesenteric lymph node were evaluated for lesions consistent with Aleutian disease (AD) 
so that subclinical disease would be detected. ADV-Utah 1-infected mink (3/3) displayed 
widespread, moderate to marked plasmacytic, lymphocytic cellular infiltration in at least 
two of the four organs examined. Li addition, glomerulonephritis or mesangial
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TABLE 7.2. Induction of hypergammaglobulinemia by Aleutian mink disease parvovirus
chimeras4
Vims
Baseline Final Difference
mean (%) +/-SEM mean (%) +/- SEM mean +/-SEM
Mock 16.1 3.3 17.3 2.5 1.2 1.2
ADV-Utah l bc 13.7 1.0 37.3 0.2 23.5 1.1
ADV-Gb 15.4 2.3 17.0 1.3 1.6 2.5
ADV-G/U-13 15.7 3.2 18.3 2.7 2.6 1.1
ADV-G/U-10 11.8 0.7 21.6 5.4 9.8 5.5
ADV-G/U-14 13.5 1.5 15.8 1.9 2.3 0.9
ADV-G/U-15 13.9 0.1 33.1 7.5 19.2 7.5
ADV-G/U-8 12.5 0.9 28.9 6.3 16.4 5.7
a Electrophoretograms of mink sera were analyzed by laser densitometry and integration 
of the area under the curve. Numbers represent the percent contribution of gamma 
globulins to total serum protein.
b Three mink per group. One mink from the ADV-Utah 1 group died of unknown causes, 
and one mink from the ADV-G group died from causes unrelated to Aleutian disease 
prior to the experimental endpoint. All other groups contained four mink. 
c Final samples were collected approximately 60 days post infection (dpi) from mink 
infected with ADV-Utah 1. All other groups were sampled at 120 dpi.
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thickening in the glomerular basement membrane was seen, indicating severe renal 
disease. These are lesions associated with classical AD (164). Tissue specimens from 
mock-, ADV-G-, and ADV-G/U-13-infected mink did not show evidence of AD. Mink 
infected with ADV-G/U-8 (4/4) had histopathologic lesions consistent with AD varying 
from mild to severe (Table 7.3). One of these mink had lesions suggestive of progressive 
renal disease. The ADV-G/U-15-infected group had similar findings (3/4) with two mink 
exhibiting severe glomerular lesions. The groups infected with chimeras containing four 
capsid changes, ADV-G/U-14 and ADV-G/U-10, showed slightly milder histopathologic 
lesions compared to ADV-G/U-8 and -15. ADV-G/U-14 mink (3/4) had mild, focal 
lesions in the mesenteric lymph node and occasionally the liver characterized by 
plasmacytic, lymphocytic infiltrates. Affected ADV-G/U-10 mink (2/4) had widespread, 
moderate infiltrative lesions of the mesenteric lymph node and liver. There were no mink 
infected with ADV-G/U-14 or -10 that showed renal lesions typical of classical, 
progressive AD. These microscopic data confirmed that the chimeras ADV-G/U-8, -15, - 
14, and -10 were all capable of inducing histopathologic lesions consistent with AD in 
sapphire mink. However, only mink infected with ADV-G/U-8 or -15 had lesions severe 
enough to suggest progressive disease. The clinical significance of mild to moderate 
histopathologic lesions is difficult to determine since histopathology alone cannot predict 
whether mink will recover from or succumb to ADV infection. The only chimera 
associated with AD-consistent tissue lesions in all mink infected was ADV-G/U-8, the 
clone containing five capsid and three nonstructural amino acid changes.
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TABLE 7.3. Incidence and severity of histopathologic lesions in mink infected with 
Aleutian mink disease parvovirus (ADV)a
Virus
Histopathologic lesions6
None Mild Moderate Severe
Utah 1 3
Mock 4
ADV-G 3
G/U-13 4
G/U-10 2 2
G/U-14 1 3
G/U-15 1 1 2
r r  ▼ r* .
K J / U - O  |___________________ |_________Z_________ |_________ I__________ 1
a Tissue samples from the left lateral lobe of the liver, tail of the spleen, left kidney, and 
mesenteric lymph node were obtained at 60 days postinfection (dpi) for ADV-Utah 1- 
infected mink and 120 dpi for all others. Tissues were embedded in paraffin, stained with 
hematoxylin-eosin, and evaluated by light microscopy.
b Histopathologic lesions were graded by a board-certified veterinary pathologist (WJH). 
In general, mild lesions were focal infiltrations of plasma cells and lymphocytes into one 
or more tissues. Moderate lesions were more widespread than mild ones and contained 
more abundant cellular infiltrates. Severe lesions included hepatic or renal arteritis and 
massive, diffuse plasmacytic, lymphocytic infiltrates.
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This study examined the differences in in vivo replication and pathogenesis 
between ADV-G/U-8 and ADV-G/U-10, two previously reported viruses chimeric 
between nonpathogenic ADV-G and highly virulent ADV-Utah 1 (138). ADV-G/U-8 
was associated with higher antiviral antibody titers and more severe histopathologic 
lesions even though it contained only one amino acid difference in VP2 and three in NS 1 
compared to ADV-G/U-10 (138). Antibody responses and incidences of 
hypergammaglobulinemia and histopathologic lesions in our present experiments showed 
that the valine residue of ADV-G/U-8 at codon 352 (V352) of the VP2 protein substituted 
for the isoleucine of ADV-G/U-10 is primarily responsible for the differences in antibody 
responses and pathogenesis between these two viruses. Previous studies in our laboratory 
demonstrated that the presence of V352 alone in an ADV-G background produced a low, 
but persistent, antibody response but was not associated with histopathologic lesions 
(166). The current experiments, however, strongly indicated that V352 had a cooperative 
effect when present with the other four ADV-Utah 1 VP2 amino acid changes previously 
determined to comprise the minimal capsid region determining in vivo replication (138). 
Not only did V352 appear to enhance in vivo replication, but it may also have contributed 
to the severities of both hypergammaglobulinemia and disease at the tissue level.
The mechanisms by which V352 may influence in vivo replication, antibody 
responses, and pathogenesis are not known. We speculate that it may be due to changes 
in capsid surface structure induced by the V352 substitution for isoleucine. ADV VP2
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residue 352 is thought to lie just below the capsid surface near the three-fold axis based 
on cryo-electron microscopy-based structural modeling (189). Parvovirus surface 
structure determines antigenic epitopes, cell receptor binding, and virus particle stability 
(116). The surface conformational changes generated by V352 may increase viral 
antigenicity and virus binding and entry into target cells. These effects would logically be 
associated with higher antibody responses and improved total viral replication as a result 
of more efficient target cell infection.
The effects of V352 on antibody responses, viremia, hypergammaglobulinemia, 
and histopathologic lesions were most clearly demonstrated when the three ADV-Utah 1 
NS 1 amino acid changes were present concurrently in the chimeras differing by only 
V352 (ADV-G/U-8 and ADV-G/U-14). Even though the three NS 1 changes alone in this 
smdy (ADV-G/U-13) or larger segments of ADV-Utah 1 NS1 in a previous study (137) 
did not alter vims replication or pathogenesis, NS 1 may play a role in replication and 
pathogenesis once a critical number of ADV-Utah 1 capsid changes are present. It is 
possible that vims capsid changes required for efficient cell binding, entry and replication 
must be present before the effects of NS 1 are evident. The presence of the NS 1 amino 
acid changes and non-coding nucleotide change may play a role in eliciting a more 
predictable and repeatable host response to the vims. This could occur either as a direct 
result of altered NS 1 protein function or as an indirect effect of coding or noncoding 
changes on the downstream P36 promoter that controls transcription of the capsid gene. 
While none of the chimeras in this study showed the reproducibility of ADV-Utah 1 vims 
infection, the most ADV-Utah 1-like chimera, ADV-G/U-8, approached it most closely.
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More studies involving larger regions o f the nonstructural gene concurrent with multiple 
capsid changes are necessary to clarify the role of NS 1 in in vivo replication and 
pathogenesis.
It was interesting that the histopathologic lesions associated with infection by the 
currently studied pathogenic chimeras were consistent with AD. These data were in 
contrast to previous findings of an unusual diffuse hepatic microvesicular steatosis seen 
with infection of a point mutant of ADV-G (166). This mutant contained a histidine to 
aspartic acid change at codon 534 of VP2 in an ADV-G background (166). The H534D 
mutant was also able to elicit a persistent, moderate antibody response and transient 
viremia (166). These data and results from the present study confirmed the importance of 
both the H534D and I352V capsid amino acid changes in in vivo replication and 
pathogenesis. Although neither change alone caused classical AD, it was apparent that 
the interactions of these two residues with other amino acid(s) was necessary for the 
induction of antibody responses and histopathologic lesions characteristic of AD. Since 
AD-like lesions were associated with chimeras containing the four amino acid changes in 
the minimal VP2 determinant region for in vivo replication (H395Q, N434H, N49 IE, 
H534D), at least one of the other three amino acid changes must have interacted with 
H534D to alter its unusual pathogenesis to signs more typical of AD. Further molecular 
experiments are necessary to define the minimum number of capsid changes necessary for 
interaction sufficient to precipitate AD in mink. These experiments may be limited by the 
ability of chimeras to replicate in CrFK, a necessary step for propagating chimeric vims 
stocks in vitro until an alternative system is found in which ADV-Utah 1-like viruses can
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be serially passaged.
Studying viral replication and pathogenesis in an out-bred animal species can be 
challenging when data are highly variable. However, there was excellent agreement 
between different measured parameters in this study. The presence of histopathologic 
changes correlated well with other data in this study. Hypergammaglobulinemic (eight) 
and viremic (seven) chimera-infected mink all showed evidence of histopathologic 
changes consistent with AD. Of the chimera-infected mink, eight had gamma globulin 
changes of greater than 10 between baseline and final sample percentages. All eight of 
these mink were diagnosed with AD histopathologically. Seven chimera-infected mink 
were viremic at one or more time points during the study. All of these animals were 
positive for histopathologic lesions of AD. The only mink diagnosed with AD by 
histopathology that was neither hypergammaglobulinemic nor viremic had a persistently 
robust anti-ADV antibody response with a positive titer at a dilution of 1:1024. The 
correlation of these data strengthen the individual findings and support the diagnoses of 
AD in affected mink.
In conclusion, our current studies established the importance of V352 of the ADV 
VP2 protein in contributing to in vivo replication and pathogenesis in mink. While 
definite roles for V185, N326, and M378 of the NS1 protein were not determined, it is 
likely that one or more of these residues or a noncoding change may have influenced the 
predictability of the host response to the virus. Our conclusion is that there may be an 
interactive relationship between the effects of capsid and nonstructural proteins or their 
gene sequences on replication and pathogenesis of ADV in mink.
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CHAPTER 8
SHEDDING OF ALEUTIAN MINK DISEASE PARVOVIRUS IN URINE MAY
BE A ROUTE OF VIRUS TRANSMISSION AND ENVIRONMENTAL
CONTAMINATION
INTRODUCTION
The successful prevention of viral disease is based on understanding the biology 
and transmission of the virus. The virus can then be avoided or immunization used to 
prevent productive infection. An effective commercial vaccine for Aleutian mink disease 
parvovirus (ADV) has not been developed. In fact, experimental vaccination of mink 
with ADV capsid proteins enhances rather than prevents disease (114). While body 
fluids have long been suspected of shedding ADV (personal communication, Dr. William 
J. Hadlow, 1999), no definitive evidence has proven a mode of transmission for 
infectious virus particles.
Evidence from canine parvovirus (CPV) demonstrates how important the spread 
of infectious vims particles in body fluids can be. During the acute phase of CPV- 
induced gastroenteritis, infectious CPV particles can be found in the saliva and vomitus 
of infected dogs (169). The major distribution of virus particles, however, is in the feces. 
Up to 109 median tissue culture infectious doses (TCJOD50) per gram of feces can be 
detected during acute disease, and only 103 T d D S0 axe necessary for infection of 
susceptible dogs (169). In addition, parvoviruses are known to be highly stable vims
77
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particles, resistant to environmental conditions that would rapidly kill other viruses, such 
as retroviruses. ADV particles are resistant to heating at 37°C for 8 hours, 56°C for 30 
minutes, ether treatment for 17.5 hours, and 1:300 formalin treatment for 4 hours (164). 
Canine parvovirus is believed to survive in soil for up to 12 months or longer (169). 
Therefore, the release of infectious ADV particles into the environment through body 
fluids could be a major source of disease transmission and ranch contamination that could 
be particularly difficult to disinfect completely.
The dispersal of ADV particles in the urine was suspected based on the known 
pathophysiology of Aleutian disease (AD). Glomerulonephritis resulting from immune 
complex deposition has long been suspected as the immediate cause of fulminant renal 
failure and death of infected mink (206,207). We suspected that as glomerular lesions 
progressed, the small ADV particles (25 nm diameter) might be able to leak through 
damaged glomeruli into the urine. Alternatively, low-level ADV replication has been 
documented in renal tubular cells (194). Lysis of these cells at the end-stage of infection 
might allow release of vims particles directly into the renal tubules and, subsequently, the 
urine. Detection of viruses in clinical urine samples can, however, be challenging since 
many viruses are often found in only small amounts in cell-free body fluids (175,196). In 
addition, urine samples often contain non-proteinaceous substances that can inhibit 
standard molecular biology reactions, such as PCR (129,165,175).
The purpose of the current experiments was to determine if viral DNA of ADV 
could be detected by PCR in the urine of mink experimentally infected with a highly 
pathogenic isolate, ADV-Utah 1.
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In order to isolate any viral DNA away from PCR inhibitors present in mink urine, 
all positive controls were processed for DNA purification using either a polyethylene 
glycol precipitation protocol (129) or a commercial kit as described in materials and 
methods (see Chapter 6). Positive control samples processed by polyethylene glycol 
precipitation did not produce a PCR product. However, positive controls purified using 
the commercial kit generated appropriately sized PCR products. We determined that the 
commercial was easier to use and was reliable for isolating parvovirus DNA from mink 
urine samples.
All three mink from the first study were negative by PCR at 0 and 10 days 
postinfection (dpi) with ADV-Utah 1. Three of three mink were positive by PCR at 56 
dpi. Of two mink for whom there were sufficient 30 dpi samples, one was negative and 
one was positive (Table 8.1). None of these mink were displaying clinical signs of AD at 
30 dpi, but all were clinically sick by 56 dpi. One ADV-Utah 1-infected mink from the 
second study showed results similar to those from the first study. This mink did not have 
viral DNA detected until 43 dpi. However, the other mink in the second study was 
positive beginning at 14 dpi and remained positive at both 28 and 43 dpi (Table 8.1).
These data showed that viral DNA may be present in the urine of ADV-Utah 1-infected 
mink as early as 14 dpi, while ADV infection is still subclinical.
Estimates of the amount of viral DNA present in two of the 60 dpi samples (mink 
5716 and 5717) were made by comparing PCR-ampIified dilutions of these samples with
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TABLE 8.1 Detection of ADV DNA in urine samples from sapphire mink by PCRa
Vims Mink Days Postinfection
Experiment 1 0 10 14 2 8 -3 0 43 56 120
Mock
5719 neg neg neg
5721 neg neg neg
ADV-Utah 1
5714 neg neg neg POS
5716 neg neg POS POS
5717 neg neg neg POS
Experiment 2 0 10 14 2 8 -3 0 43 56 120
Mock
5748 neg neg neg
5749 neg neg neg
ADV-G 5758 nee nee- neg
5759 neg neg neg
ADV-Utah 1 5784 POS POS POS
5785 neg neg POS
1 DNA was extracted from urine samples (140 pi) using a Viral RNA Mini Kit (Qiagen, 
Valencia, CA). 2.5 pi of purified DNA (final volume after elution, 60 pi) was used as 
template for a PCR reaction amplifying a 692-bp fragment of the VP2 gene of ADV-G.
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dilutions of a known standard. Approximate virion DNA amounts were 1 x 105 (5716) 
and 2 x 103 (5717) viral genomes/ml of urine. These results confirmed that while varying 
amounts of viral DNA were present in different animals, there was ample viral DNA 
present to substantially contaminate the environment and to infect other animals if the 
viral DNA was present in infectious virus particles.
In order to determine if the viral DNA detected by PCR was associated with 
infectious vims particles, filtered urine from mink 5716 and 5717 was used for IP 
injection of healthy mink. These animals developed antiviral antibody titers and viremia 
by 30 dpi (Table 8.2). These mink will be monitored until signs of clinical illness are 
evident, at which time assays for hypergammaglobulinemia and gross and microscopic 
examinations will be done to confirm the presence of classical AD. Verification of the 
development of AD will prove that infectious parvovirus particles were present in urine 
samples of ADV-Utah 1-infected mink.
DISCUSSION
In these experiments, we proved that ADV DNA can be found in the urine of 
ADV-Utah I-infected mink. This is an important step toward identifying a mode of 
transmission for ADV. While the presence of viral DNA does not assure the presence of 
infectious vims particles, it is suggestive that urine may be a route for the shedding of 
ADV.
Also of interest is the concentration of viral DNA detected. One mink had
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Table 8.2 Serological responses of sapphire mink injected with filtered urine
from ADV-Utah 1-infected mink
Virus Mink
Antiviral Antibody Titers3 Serum Viremiab
Days Postinfection
0 10 30 0 10 30
Mock
5786 neg neg neg neg neg neg
5787 neg neg neg neg neg neg
ADV-Utah 1
5788 neg neg 1:1024 neg POS POS
5789 neg neg 1:64 neg neg POS
5790 neg neg 1:16 neg neg POS
5791 neg neg 1:1024 neg neg POS
a Antiviral antibody titers were measured by counterimmunoelectrophoresis using serial 
four-fold dilutions of serum.
b Serum viremia was measured by using serum as template for an ADV-specific PCR 
reaction amplifiying a 692-bp fragment of the VP2 gene of ADV-G.
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approximately 1 x 105 viral genomes/ml. Mink can be productively infected with ADV- 
Utah 1 with as little as three orders of magnitude less virus than this. All three mink 
tested were confirmed in renal failure based on inappropriate urine concentration in the 
face of azotemia or clinical dehydration. Subsequently, all three had abnormally dilute 
urine samples. These mink were also assessed to be in polyuric renal failure, so they 
were urinating more frequently and in greater volumes than normal. These data suggest 
that if the viral DNA we detected is present in infectious virus particles, large numbers of 
infectious virus particles could be shed by these mink that are urinating increased 
amounts of dilute urine that already contains a substantial amount of vims. This could be 
the source of extensive environmental contamination.
The next step in determining if urine is the source of infectious ADV particles is 
to demonstrate infectivity in these samples. Experiments are currently underway in which 
sapphire (Aleutian genotype) mink have been injected IP with filtered urine samples from 
the mink of this report. They are being examined and tested for signs of classical AD. 
Signs of disease consistent with AD will be convincing evidence that infectious vims 
particles are shed in the urine of ADV-Utah 1-infected mink.
The spread of infectious ADV in mink urine has far-reaching implications. The 
most important impact is on mink ranchers. Knowing the mode of transmission of ADV 
may help them target environmental and property disinfection after outbreaks. It also 
indicates the importance of possible fomite transmission, so ranchers can be more careful 
about buying equipment or caging from ranches that have recently had outbreaks of ADV. 
In addition, ADV can infect not only mink, but also ferrets, weasels, fishers, martens,
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striped skunks, and raccoons (180,197). Environmental contamination with a  virus that is 
resistant to heat, cold, and many chemicals creates a situation in which neighboring 
wildlife may be at increased risk for infection and spreading the disease themselves. 
Domestic ferrets {Mustela putorius) are closely related to mink (Mustela vison) and are 
popular as household pets as well as being raised commercially. ADV in pet ferrets 
usually presents as coughing or other respiratory signs and progressive posterior paresis 
several weeks later (221). The route of transmission of ADV between ferrets has not 
been established yet, but those raised on ferret ranches that have had ADV on the 
property may be at increased risk. The results of our final experiments will verify 
whether these concerns are valid.
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CHAPTER 9
ISOLATION OF MINK ALVEOLAR TYPE H EPITHELIAL CELLS
INTRODUCTION
The productive infection of alveolar type II epithelial cells (or type II 
pneumocytes) with Aleutian mink disease parvovirus (ADV) in mink kits (121) causes 
severe interstitial pneumonia (117) and probably decreased surfactant production (118), 
which contributes to severe respiratory distress and death. The infection of alveolar type 
II epithelial cells is considered permissive since the virus replicates to very high copy 
numbers of both single stranded virion and double stranded replicative form DNA (5 x 
104 - 1 x 105) (121). Large numbers of ADV-specific mRNA transcripts have also been 
demonstrated (120). The only immortalized cell line in which some isolates of ADV will 
replicate permissively is Crandell feline kidney (CrFK) cells (120,121). Although 
elaborate studies have been done using the CrFK system to analyze subcellular aspects of 
permissive ADV infection (198-200), it is not known if the same events occur in the 
natural host cell, alveolar type II epithelial cells.
Rat and human alveolar type II epithelial cells have been successfully isolated 
from lung tissue and cultured ex vivo (150,152,160,161,174,188,213,216). In addition to 
supporting viral replication (150), alveolar type II epithelial cells also show a variety of 
interesting immune functions, including complement production (216), arachidonic acid 
release and metabolism (152), and expression of major histocompatibility complex
85
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(MHC) class II molecules (174). The major known functions of these cells, however, are 
the production and release of surface active phospholipid materials (surfactant), the repair 
of airway epithelium, and limitation of leakage of solutes and fluid into the alveolar air 
spaces (213). These immunological, functional, and structural properties make type II 
pneumocytes critical to normal airway health and their metabolism unique compared to 
many immortalized cell lines.
The purpose of the current work was to determine if mink type IE pneumocytes 
could be isolated and cultured ex vivo and support ADV infection. Our goal was to define 
a primary cell culture system that could be used to study the subcellular events of 
permissive ADV infection.
METHODS
Alveolar type II epithelial cell isolation protocol. Methods used for alveolar type II 
epithelial cell isolation were modified from previous work by Dobbs, et. al. (161), and 
Castleman, et. al. (150). Rats were first used to learn the technique, and then isolations 
were done using mink. Briefly, the isolation process involves flushing contaminating 
cells from the vasculature and airways, digesting the lung tissue with enzymes, then 
separating type II cells from alveolar macrophages. A detailed protocol for alveolar type 
II epithelial cell isolation follows:
1) Rats were anesthetized with pentobarbital IP (80 mg/kg) and mink with
acepromazine and ketamine IM. They were then administered heparin sodium
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(400 IU/kg) either IP (rats) or IV (mink). The length of the sternum and ventral 
cervical area were clipped and aseptically prepared with betadine solution and 
70% ethanol.
2) A ventral midline thoracotomy incision was made, the thorax opened, and the 
animal exsanguinated by direct intracardiac puncture. The dorsal aorta was 
transected midthorax, and the caudal vena cava, cranial vena cava, and azygous 
veins were clamped with hemostats to prevent retrograde flow of flush solutions.
A 22 gauge IV catheter was passed into the right ventricle of the heart and 
threaded into the pulmonary artery. The stylet was removed, and the lung 
vasculature was flushed with Solution II [140 mM NaCl, 5 mM Kcl. 2.5 mM 
phosphate buffer, 10 mM HEPES (iV-2-hydroxyethylpiperazine-AT-2- 
ethanesulfonic acid), 2.0 mM CaCl2, and 1.3 mM MgSOJ until the lungs were 
blanched white. This usually required about 20 - 60 ml for rats and 120 - 240 ml 
for mink in 60-cc syringes. The lungs were carefully removed from the thorax as 
well as the length of the trachea and placed in phosphate buffered saline solution 
for transport to the laboratory.
3) The open end (oral) of the trachea was cannulated with a metal teat cannula (rats) 
or a soft rubber feeding tube (mink) and tied snugly with nonabsorbable suture to 
prevent slipping. Bronchoalveolar lavage (BAL) was done eight (8) times using 
Solution I [140 mM NaCl, 5 mM Kcl, 2.5 mM phosphate buffer, 10 mM HEPES,
6 mM glucose, 0.2 mM EGTA (ethylene glycol-bis-(P-amino ethyl ether), N, N’- 
tetraacetic acid), pH 7.4] in volumes sufficient to fully inflate the lungs. Wash
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fluid was saved in 50-ml conical centrifuge tubes for alveolar macrophage 
isolation. Two (2) final BAL washes were done using Solution II and discarded. 
For continuation of alveolar macrophage isolation, see the section immediately 
following type H cell isolation protocol.
4) The lungs were inflated with Solution II containing 30 orcein units/ml elastase (or
4.3 units elastase measured by succinyl-(L-alanine)3-p-nitroanilide) (161). The 
cannula was sealed to maintain Solution II in the lung. The lung tissue was 
incubated in a large covered petri dish at 37°C for 20 min.
5) The large cartilaginous airways were excised and the lung tissue minced with 
sterile scissors, then with a sterile razor blade. The lung tissue was covered in 4 
ml fetal calf serum, 5 ml DNAse solution (250 pg/ml), and adjusted to a final 
volume of approximately 40 ml with Solution II. The final suspension was 
shaken in a 50-ml conical centrifuge tube at 37°C for 30 min.
6) The suspension was filtered through 2 layers sterile cotton gauze, then 4 layers, 
then sterile nylon mesh (150 pm pores) into 50-ml conical centrifuge tubes. The 
filtered cells were washed 2 times with Solution II at 130 g for 8 min at 10°C.
7) The cell pellet was resuspended in 4 ml Dulbecco’s modified Eagle medium 
(DMEM) with 0.1 mg/ml bovine serum albumin and 0.6 mg Griffonia 
simplicifolia lectin/4 ml and was incubated at 37°C for 30 min, mixing gently 
every 5 min. Griffonia simplicifolia lectin I agglutinates alveolar macrophages 
but not type II pneumocytes (213). A reddish-brown precipitate was evident after 
the incubation. The suspension was filtered through a 20 pm mesh into a 15-ml
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conical centrifuge tube and centrifuged at 130 g for 10 min.
8) The resulting cell pellet was resuspended in 10 ml plain DMEM and panned onto 
a rat IgG-coated plastic bacterial culture plate prepared as described by Dobbs, et. 
al. (161). The plate was incubated at 37°C for 1 h. Loose cells were gently 
removed from the plate by rocking back and forth. The nonadherent cells were 
transferred to a 15-ml conical centrifuge tube and centrifuged at 130 g for 8 min.
9) The final cell pellet was resuspended in a volume of DMEM with 10% fetal calf 
serum appropriate for the experiments to be done. Cells were seeded at a density 
o f 2 x  10s to 5 x 105 cells per well in basement membrane-coated (1:10 dilution in 
plain DMEM of Matrigel, Collaborative Research Inc., Bedford, MA) 24-well 
plates and incubated at 37°C for 5 days. Half of the medium was replaced every 
other day.
Alveolar macrophage isolation protocol. Alveolar macrophages were isolated from the
BAL fluid collected in step 3 above. A detailed protocol for the remainder of alveolar
macrophage isolation follows:
1) 50-ml conical centrifuge tubes containing BAL fluid were centrifuged at 130 g for 
8 min at 10°C. Supernatant was decanted and the cell pellet washed twice more 
with phosphate buffered saline solution.
2) The final cell pellet was resuspended in DMEM with 10% fetal calf serum. Cells 
were seeded at a density of 5 x 10s cells per well in basement membrane-coated 
24-well plates as for alveolar type H pneumocytes above. Half of the medium was 
replaced every other day.
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Cell morphology and  purity. Alveolar type II epithelial cells and alveolar macrophage 
cultures were examined daily using an inverted light microscope. Samples were collected 
immediately after isolation for cytocentrifiige to assess cell morphology and purity. Cells 
were fixed with tannic acid and stained using a polychrome stain as described by Mason, 
et. al. (187), and examined by light microscopy.
Ultrastructure. Cells were seeded on basement membrane-coated cell well inserts with 
a pore size of 3.0 pm. Inserts were fixed for transmission electron microscopy two to 
three days later. Standard fixation procedures including cacodylate-buffered 
glutaraldehyde and tannic acid were used in the Microscopy Branch of The Rocky 
Mountain Laboratories.
Virus infections. Experiments were done trying to infect alveolar type II pneumocytes 
and alveolar macrophages with 1:10 dilutions of either ADV-G or ADV-Utah 1 kit vims. 
Cells were seeded into basement membrane-coated wells in a volume of 225 pi. 25 pi 
vims stock was added to create a 1:10 dilution of vims. Plates were incubated at 37°C for 
90 min, then 1.75 ml of medium were added and plates returned to the incubator for the 
remainder of the experiment. Cells were trypsinized and cytocentrifuged for fluorescent 
antibody staining at 24,48, 72, 96, and 120 h postinfection. Mock-infected controls were 
harvested at 48 and 120 h postinfection.
Fluorescent antibody staining. Cytocentrifuged specimens were fixed in acetone for 10 
min, rinsed with 70% ethanol, and air-dried. Slides with fixed specimens were stored at - 
20°C until fluorescent staining was done. Slides were blocked for 30 min with 10% 
normal mink semm and then directly stained with fluorescein-conjugated polyclonal mink
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serum that recognized capsid and nonstructural proteins. Differential staining was done 
using rabbit-generated anti-capsid or anti-nonstructural antibodies or a monoclonal anti- 
capsid antibody (Mab 165). Slides were mounted with anti-fade mounting medium and 
were viewed with a fluorescent microscope.
RESULTS
Isolation procedure. Alveolar type II epithelial cells were successfully isolated from the 
lungs of both rats and mink. The most difficult aspect of the isolation procedure was 
achieving adequate clearance of blood from the pulmonary vasculature. Transection of 
the aorta to allow an exit for the flush solution and clamping the large veins to prevent 
retrograde flow were the two most important steps necessary to attain complete clearance 
of the pulmonary vessels. These types of procedural details are best described by Mason, 
et. al. (188), and Simon, et. al. (213).
Cell morphology, purity, and yield. In order to assess the morphology and purity of 
isolated cells, cytocentrifuge samples were made immediately after type II pneumocyte 
and alveolar macrophage isolation. Type II pneumocytes were easily identified as they 
contained large round cytoplasmic inclusions, called lamellar bodies, that stained deeply 
brown with tannic acid alone (Figure 9.1, A) or bluish-brown with the addition of 
polychrome stain (Figure 9.1, B and C). Lamellar bodies contain phospholipids that 
contribute to surfactant. Immediately after isolation, type II pneumocytes accounted for 
approximately 65% to 85% of the cell population. These numbers increased to 85% to
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Figure 9.1. Cytology of mink alveolar type II epithelial cells immediately after isolation. 
(A) shows type II pneumocytes fixed with tannic acid and magnified 20X. Mink type II 
pneumocytes have brown-staining cytoplasmic inclusions, or lamellar bodies. Lamellar 
bodies contain phospholipids that contribute to surfactant. (B) is a 20X magnification of 
mink type II pneumocytes fixed with tannic acid and stained with a polychrome stain 
(187). Macrophages are slightly larger than type II pneumocytes and do not contain 
lamellar bodies. Four macrophages are located in the center of the photograph. One 
macrophage contains phagocytosed particles in the cytoplasm. They can be distinguished 
from lamellar bodies based on their variable sizes and shapes. (C) shows a 40X 
magnification of mink type II pneumocytes stained as in (B). All cells seen are type II 
pneumocytes with the exception of one macrophage in the lower right comer of the 
photograph.
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90% after two to three days in culture. Total type II pneumocyte cell yield from each 
mink varied from 4 x 106 to 7 x 106. Alveolar macrophage cultures were approximately 
95% pure immediately after isolation. Macrophages were distinguished from type II 
pneumocytes by their peripheral cytoplasmic extensions (187) (Figure 9.2, A), 
multinucleated cells (Figure 9.2, B), and their general lack of cytoplasmic inclusions. 
When cytoplasmic inclusions were present (Figure 9.1, B), they were of unequal sizes and 
shapes and stained a deep red rather than bluish-brown color.
The organization of type II pneumocytes in cell culture changed over time similar 
to rat type II pneumocytes as described by Castleman, et. al. (150). Initially, cells were 
round and arranged individually in a monolayer covering the bottom of 24-well plate 
wells. Lamellar bodies were apparent as clear, refractile areas in the cytoplasm of type II 
pneumocytes by light microscopy. By 48 h postinfection, the type II pneumocytes were 
arranged in small circular groups with an internal lumen, and individual cells appeared 
more teardrop-shaped than round. Between two and five days postinfection, these cell 
aggregates appeared to expand upward towards the medium surface.
U ltrastructure. Transmission electron microscopy (TEM) confirmed the presence of 
lamellar bodies in the rat (not shown) and mink (Figure 9.3, A) alveolar type II epithelial 
cells. The “onion skin” appearance of the layers of phospholipids within these inclusions 
is very distinct, and surfactant can occasionally be seen as it extrudes from the cell 
membrane (Figure 9.3, B). Other contaminating cells seen by TEM included 
polymorphonuclear, monocytic, and ciliated bronchial epithelial cells.
Virus infections. Rat alveolar type II epithelial cells never showed evidence of infection
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Figure 9.2. Cytology of alveolar macrophages immediately after isolation. (A) shows 
alveolar macrophages fixed with tannic acid and stained with a polychrome stain (187). 
The cytoplasm of alveolar macrophages stains pale to medium pink compared to the 
deeper blue seen in type II pneumocytes (see Figure 9.1). A magnification of 40X reveals 
the peripheral cytoplasmic extensions that help distinguish macrophages from alveolar 
type II epithelial cells (187). In (B), a multinucleated macrophage is present. 
Multinucleation also distinguishes macrophages from type II pneumocytes.
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Figure 9.3. Transmission electron microscopy of mink alveolar type It epithelial cells 48 
hours after isolation. A type II pneumocyte is seen in (A) containing several lamellar 
bodies in its cytoplasm (17,400X). Inside the lamellar bodies is the characteristic “onion­
skin” pattern created by the arrangement of the polar heads of the phospholipids 
contained within the lamellar bodies. (B) shows a portion of a type II pneumocyte at a 
magnification of 90,000X. A small lamellar body is being extruded from the cell. The 
ultrastructural features of lamellar bodies seen by transmission electron microscopy 
confirmed the identity of these cells as alveolar type It epithelial cells.
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with either ADV-G or ADV-Utah 1 as determined by fluorescent antibody staining in two 
separate experiments per virus. Mink type II pneumocytes and alveolar macrophages 
never appeared infected with ADV-G in two separate experiments. However, mink type 
II pneumocytes incubated in the presence of ADV-Utah 1 showed both cytoplasmic and 
nuclear staining between three and five days postinfection reminiscent of ADV-G- 
infected CrFK (Figure 9.4) in three different experiments. When specific staining was 
done to identify capsid and nonstructural proteins, however, no staining was seen. The 
primary antibodies and secondary fluorescent antibodies worked well on control ADV-G- 
infected CrFK cells that were stained simultaneously with the type II pneumocytes.
DISCUSSION
Alveolar type II epithelial cells were successfully isolated from the lungs of 
sapphire mink. By gross examination, they appeared to survive well in culture for up to 
five days after isolation and displayed morphological characteristics described for rat type 
II pneumocytes (150,187,188). The purity of cultures was similar to that reported for rat 
type II pneumocytes (160,188,213) purified using similar steps. Increased initial purity 
may be possible by including density centrifugation or additional filtering steps, but the 
loss in yield may be prohibitive.
The total yield of type H pneumocytes per mink was disappointing compared to 
numbers reported for rats (161). However, earlier literature suggested that the supplier 
and the housing conditions substantially altered the yield of type II pneumocytes in rats
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Figure 9.4. Fluorescent antibody staining of mink alveolar type II epithelial cells 
incubated with ADV-Utah 1. All panels show cytocentrifuge specimens of mink alveolar 
type II epithelial cells stained with a 1:15 dilution of fluorescein-conjugated polyclonal 
anti-ADV mink serum. (A) illustrates mock-infected cells 48 hours after infection. No 
cellular staining is evident. (B) shows two positively staining cells. In the upper cell, 
nuclear and cytoplasmic staining is evident while the lower cell has nuclear staining only. 
(C) illustrates type II pneumocytes 72 hours postinfection with ADV-Utah 1. Nuclear 
and cytoplasmic staining is evident in one cell. (D) is an example of type II pneumocytes 
120 hours postinfection. A small cell adjacent to a larger cell shows both nuclear and 
cytoplasmic staining. While these panels suggest that ADV replication is occurring in the 
nucleus, viral protein-specific stains did not demonstrate the presence of nonstructural 
proteins.
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from 8 x 106 to 20 x 106 cells/rat (188). Our yields were comparable to those for non­
specific pathogen free rats without special housing. However, increased yields would 
substantially improve the ability to set up adequate repetitions of experiments with cells 
isolated from one animal. This can be a difficult task as it is estimated that alveolar type 
II epithelial cells account for only 14% of total cells in the lungs of rats (159).
Although with polyclonal anti-ADV serum there appeared to be positive staining 
in mink type II pneumocytes incubated with ADV-Utah 1, we were discouraged that viral 
protein-specific staining did not yield positive results. We speculate that the viral 
proteins in the type II pneumocytes may be degraded. While it is common for ADV 
proteins to be degraded in infected mink, polyclonal antiserum should contain antibodies 
directed against epitopes of degraded viral proteins. This may not be the case with rabbit 
or mouse antibodies generated against specific protein preparations. It is also possible 
that the staining we saw with polyclonal antiserum is artifactual. The argument against 
this explanation is that the patterns of staining were identical to those seen in CrFK cells 
infected with ADV-G. Finally, only very few cells exhibited positive staining. It is 
possible that the incidence of infection was so low that specimens stained with protein- 
specific antibodies did not contain any infected cells. More experiments are necessary to 
determine if these cells were productively infected with ADV-Utah 1.
Additional experiments that remain to be done are alveolar type II epithelial cell 
isolations from mink kits with attempted infection. Evidence from humans and from 
ferrets suggest that permissivity for herpes simplex virus and influenza vims, 
respectively, is age dependent (154,155,191). This may be due to the permissivity of type
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II pneumocytes, the lack of a mature pulmonary immune response, or both. Nevertheless, 
since there is a proven age dependency in ADV infection, it is possible that alveolar type 
II epithelial cells from mink kits may be productively infected ex vivo. Further 
experiments must be done to prove this hypothesis.
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FUTURE DIRECTIONS
In vivo replication and pathogenesis. The work presented in this dissertation and 
previous work in our laboratory (138,166) show the importance of the Aleutian mink 
disease parvovirus (ADV) capsid amino acids, V352 and D534, in in vivo replication. 
Additionally, experiments in this dissertation work demonstrate that interactions between 
multiple capsid amino acids are necessary for the induction of classical Aleutian disease 
(AD) in sapphire mink. Finally, the nonstructural gene may be playing an interactive role 
as well in influencing the consistency of host immune responses and the occurrence of 
histopathologic lesions consistent with AD. However, none of the molecular constructs 
made to date reproduce the level of in vivo replication and pathogenesis seen with ADV- 
Utah 1. There are still pieces of the puzzle that are missing.
The mapping of in vivo replication and pathogenesis determinants can continue 
along several different lines of approach. Work remains to be done with the capsid gene, 
the nonstructural gene, and combinations of the two. In order to more specifically map 
replication determinants of the capsid gene, double and triple capsid mutants need to be 
evaluated. The first combination of amino acids that is obvious is V352 and D534. This 
chimera has been constructed and awaits in vitro propagation and in vivo studies (J. M. 
Fox, unpublished data). Additional combinations of three amino acid changes may help 
resolve which other single amino acid change in addition to V352 and D534 could 
contribute to in vivo replication and histopathologic lesions consistent with AD. These
104
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mutants would be constructed of ADV-G background with V352 and D534 in the capsid 
gene. The additional point mutations, H395Q, N434H, and N491E, would be 
individually introduced into the capsid gene for a total of three new chimeras. H395Q 
and N434H, when present in ADV-G as single point mutations, abolish the ability of 
ADV-G to replicate in Crandell feline kidney (CrFK) cells (166). It is not known if these 
mutations in combination with V352 and D534 will inhibit replication in vitro. It is also 
possible that a minimum of four capsid changes may be necessary to induce AD-like 
histopathological changes. IT necessary, additional mutants can be made after more 
information is gathered from the double and triple mutant studies.
Next, a larger portion of the nonstructural gene of ADV-Utah 1 should be studied 
in the context of the five capsid amino acid changes present in ADV-G/U-8 and -15 
(Figure 7.1, Table 7.1). Additional amino acid differences between ADV-G and ADV- 
Utah 1 in the nonstructural gene include B78M and F481L as well as a noncoding change 
at nucleotide 1705 (codon 500) (136,168). All of these changes reside upstream of the 
P36 promoter that controls transcription of the capsid gene. These changes could have 
direct effects on the nonstructural proteins or have indirect effects on the downstream 
promoter or a combination of the two.
Finally, when the influence of capsid changes are mapped more narrowly and the 
contribution of the nonstructural gene is more evident, crucial changes from each region 
should be combined in the same chimera. If this chimera replicates in vitro, it can be 
tested in mink. The only portions of the genome left unstudied at this point will be a few 
individual residues at the left end of the capsid gene, a few changes in the mid open
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
106
reading frames, and noncoding regions in the 3’ and 5’ hairpin ends that may influence 
viral replication.
An additional project that could potentially improve the quality of the antiviral 
antibody measurements made in the aforementioned experiments would compare new 
capsid antigens for use in the counterimmunoelectrophoresis (CEP) assay with the 
commercial standard currently used (United Vaccines, Madison, WI). The commercial 
antigen we currently use is derived from ADV-G. It is possible that some of the altered 
capsids created by site-directed mutagenesis have epitopes differing from ADV-G. 
Subsequently, in order to accurately measure antiviral antibody produced against these 
capsids, it may be necessary to test antiserum against virions made of these mutated 
capsid proteins. It is possible to do this by cloning the mutated capsid sequences into a 
baculovirus system, propagating the VP2 protein, and allowing self-assembly of empty 
virus particles. These virus particles could then replace the commercial antigen in the 
C E P assay. If no differences between baculovirus-generated and commercial antigens 
were seen, the commercial antigen would be retained as the standard. Alternatively, if 
virus titers are changed by using the appropriate antigen for suspected antibody produced, 
it may be necessary to generate new antigen for each new capsid construct.
Replication at the tissue level. Although we evaluate viral replication at the systemic 
level by testing serum, we have been concerned that replication may be occurring at the 
tissue level and that virus remains sequestered from the peripheral vasculature. 
Alternatively, low level replication may be below the detectable level of our PCR assay. 
Subsequently, individual tissue samples must be screened for viral DNA in order to
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determine if virus is present in various organs. Preliminary results from PCR 
amplification of purified genomic DNA isolated from liver, spleen, kidney, and 
mesenteric lymph node of chimera-infected mink in this dissertation study suggest that 
the V352 residue of VP2 may influence the ability of virus to infect the kidney (Table 
10.1). Only chimeras with five capsid changes were found in the kidney. Since volume, 
rather than mass, of DNA solutions were equalized for the PCR reactions, there was a 
potential for error when comparing results among mink. Screening agarose gels showed 
that PCR positive reactions did not correlate with samples containing the highest DNA 
concentrations. PCR reactions using mass-equalized samples have yet to be done.
In order to determine whether viral replication was occurring, in the tissues that 
tested positive by PCR, Southern blotting to probe for replicative form and virion DNA 
must be done. It is possible that the viral DNA detected by PCR is merely input virus that 
remained sequestered in organs for which the virus was most tropic. Also, target immune 
cells could traffic to these organs, carrying virus with them. It would be very interesting 
if Southern blot analysis demonstrated replicative form viral DNA in some tissues and 
not others. This kind of analysis may be helpful in learning more about the tropism and 
in vivo behavior of ADV chimeras.
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TABLE 10.1. Detection of parvoviral DNA and histopathologic lesions in mink infected
with ADV chimeras _______
M ink# Virus
PCR Results1 (120 dpi) Other
Serumb Liverc Spleen0 Kidney0 Lymph
node0
Histopathology41
5718-21 Mock
5722-24 ADV-G
5734-37 G/U-13
5726
G/U-10
X
5727
5728 X X X moderate
5729 X X X moderate
5738
G/U-14
X X mild
5739 X mild
5740 X X mild
5741
5742
G/U-15
X X X X X severe
5743 X X X
5744 X X X X X severe
5745 X X X X moderate
5730
G/U-8
X X moderate
5731 X mild
5732 X X X X X severe
5733 X X X X mild
1 DNA template samples were amplified using ADV-specific primers complementary to a 
region of the VP2 gene of ADV-G.
b Untreated serum was used as template for the PCR reaction.
c DNA template was isolated from 10 mg of spleen and 20 mg of other tissues using a 
Viral RNA Mini Kit (Qiagen, Valencia, CA). 
d Histopathology was graded as described in table 7.3.
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